

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A2

(51) International Patent Classification⁷: C12N 15/11

Venezuela (VE). MOELLERING, Robert [US/US]; 49 Longfellow Road, Wellesley Hills, MA 02481-5220 (US). GOLD, Howard [US/US]; Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). ELIOPoulos, George, M. [US/US]; 5 Laurel Circle, Needham, MA 02494 (US).

(21) International Application Number: PCT/US00/22086

(74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(22) International Filing Date: 11 August 2000 (11.08.2000)

(81) Designated States (national): CA, JP, US.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(26) Publication Language: English

Published:

— Without international search report and to be republished upon receipt of that report.

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviation" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): INOUYE, Roger, T. [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). TORRES-VIERA, Carlos [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas,



A2
WO 01/12803

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT ENTEROCOCCUS



(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a VanR-responsive promoter decoy.

-1-

METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT ENTEROCOCCUS

Related Applications

5 This application claims priority under 35 USC §119(e) from U.S. Provisional Patent Application Serial No. 60/149,313, filed on August 17, 1999, entitled METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*. The contents of the provisional application are hereby expressly incorporated by reference.

10

Government Support

This work was funded in part by the National Institutes for Allergy and Infectious Diseases/National Institutes of Health under Grant KO8 AI01518. The government may retain certain rights in this invention.

15

Field of the Invention

This invention relates to methods for reducing antibiotic resistance in vancomycin resistant bacteria.

20

Background of the Invention

Over the past decade, the emergence of antibiotic-resistant bacteria, particularly multidrug-resistant strains, have created an increasingly concerning clinical dilemma (Gold, et al., *N. Engl. J. Med.*, 1996, 335:1445-1453). Included among these pathogens are enterococci which have developed relative, and in some cases, absolute resistance to the mainstays of antimicrobial therapy, including beta-lactam and aminoglycoside antibiotics, and more recently, the glycopeptide, vancomycin (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65). While new pharmacologic agents continue to be developed in order to remedy this therapeutic shortfall, drug resistance and consequential treatment failure to even investigational agents such as the streptogramins in the setting of vancomycin-resistant enterococcal infections highlight the ongoing need for effective, potentially novel means of treating these organisms (Chang, et al., *Diag. Microbiol. Infect. Dis.*, 1999;33:299-303).

-2-

Vancomycin Resistant Enterococcus

Enterococci are Gram-positive cocci which, prior to DNA homology studies, were classified as Lancefield group D streptococci (Moellering, R.C. Jr., In: Mandell GL, Bennett JE and Dolin R eds. *Principles and Practices of Infectious Diseases*. New York:Churchhill Livingstone. 1995:1826-1835). While these organisms are known constituents of the gastrointestinal and genital tract bacterial flora, enterococci have rapidly emerged as clinically relevant pathogens especially in the nosocomial setting. In fact, enterococci are the second most common cause of nosocomial infections in the United States as well as a frequent cause of nosocomial bacteremia (Eliopoulos, G.M., *Infect. Clin. North. Am.* 1997;11:851-65); Schaberg, et al., *Am. J. Med.*, 1991;91(3B):72S-85S). Far from being inconsequential, the mortality attributable to vancomycin resistant enterococcal bacteremia has been estimated to approach 25% in some studies (Edmond, et al., *Clin. Infect. Dis.*, 1996;23:1234-1239).

Vancomycin Mechanism-of-Action

First introduced in the 1950's as a means for treating penicillin-resistant staphylococcal infections, vancomycin, a glycopolyptide antibiotic, has become the drug-of-choice for the treatment of beta-lactam antibiotic-resistant Gram-positive bacterial infections (Fekety, et al., In: Mandell, et al. *Principles and Practices of Infectious Diseases*. New York:Churchhill Livingstone, 1995;346-354). While other ancillary mechanisms-of-action continue to be investigated, the major mechanism of vancomycin is the inhibition of polymerization and transpeptidation of the bacterial cell wall peptidoglycan (Ge, et al., *Science* 1999;284:507-11). This structure serves an important function in bacteria: the inhibition of osmotic lysis. In the wildtype enterococci, cell wall production is characterized by peptidoglycan synthesis in which two D-alanines are ligated to form a dipeptide which is then added to the carboxy-terminus of peptidoglycan precursors (Walsh, C.T., *J. Biol. Chem.*, 1989;264:2393-2396). Vancomycin interferes with this process by complexing with the terminal D-alanine residues at the outer portion of the cytoplasmic membrane (Beauregard, et al., *Antimicrob. Agents chemother.*, 1995;39:791-785; Reynolds, et al., *Euro. J. Clin. Microbiol. Infect. Dis.*, 1989;943-950). This blocks subsequent cell wall formation by perturbing the further processing of peptidoglycan precursors by transglycosidases. Vancomycin also blocks catalysis by enterococcal transpeptidases and D,D-carboxypeptidases.

Vancomycin Resistance

-3-

Several phenotypes of glycopeptide resistance in enterococci have been described (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65). Class A glycopeptide resistance (VanA), which was targeted in this study, is found in both the clinically relevant *Enterococcus faecalis* and *Enterococcus faecium* species, and is characterized by high-level 5 vancomycin resistance with MICs \geq 64 $\mu\text{g/mL}$ as well as resistance to teicoplanin, a related glycopeptide antibiotic (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65).

The genotypic characterization of Class A vancomycin resistance has uncovered potential targets for gene-based anti-drug resistance determinant strategy. The genetic basis for VanA phenotypic resistance is a transposon-based operon consisting of 7 genes including 10 *vanR*, *vanS*, *vanH*, *vanA*, *vanX*, *vanY*, and *vanZ* (Arthur, et al., *Antimicrob. agent Chemother.*, 1993;37:1563-1571; Bugg, et al., *Biochem.*, 1991;30:2017-2021) (Figure 1). The products of 15 these genes function in concert to negate the inhibitory effects of vancomycin by, in essence, allowing for an alternate biosynthetic pathway for the production of cell wall precursors which less avidly bind vancomycin. The transcription of *vanH*, -*A*, and -*X* are under the control of the *vanH* promoter. This promoter is inducible by the binding of the phosphorylated gene product of *vanR* (Arthur, et al., *J. Bacteriol.*, 1992;174:2582-2591; Holman, et al., *Biochem.*, 1994;33:4625-4631).

Therapeutic Gene Transfer Background

In an attempt to inhibit pathogens which are refractory to conventional 20 pharmacological antimicrobial agents, gene-based therapeutics have been studied, though for the most part, in eukaryotic systems. For example, nucleic acid binding decoys, antisense nucleic acids (antisense RNA and DNA), ribozymes, and trans-dominant mutants are among 25 the many gene therapy motifs which have been used to target the expression of key viral functions in human immunodeficiency virus, type 1; human papilloma virus; hepatitis viruses, and Herpesviridae infections (Chatterjee, et al., *Science*, 1992, 258:1485-1488; Weiss, et al., *Cell. Mol. Life. Sci.*, 1999, 55:334-58; Yamada, et al., *Virol.*, 1996, 70:1596-1601; Inouye, et al., *J. Virol.*, 1997, 71(5):4071-4080; Yamamoto, et al., *Hepatology*, 1999, 30:300-307; Shillitoe, et al., *Cancer Gene Ther.*, 1994, 1:193-204; Flores-Aguilar, et al., *J. Infect. Dis.*, 1997, 175:1308-1316). Additionally, they have been studied for their ability to inhibit pro- 30 oncogenic cellular functions (Mercola, et al., *Cancer Gene Ther.*, 1995, 2:47-59; Seth, et al., *Cancer Gene Ther.*, 1997, 4:383-390; Rubin, et al., *Curr. Opin. Pediatr.*, 1999, 11:39-46).

A cornerstone of a successful gene-based tactic is that the target nucleic acid sequence encode for pivotal, highly conserved pathogenic functions. In eukaryotic viral and oncologic

systems, antisense nucleic acids, for example, have also been specifically used to inhibit the expression of key viral or cellular functional proteins including the expression of drug resistance determinants (Gao, et al., *Anticancer Res.*, 1998, 18:3073-3076; Inouye, et al., *Antiviral Therapy*, 1999, 4 (Supplement 1):121). In comparison, examples of gene-based 5 strategies in prokaryotic systems are scant (Takada-Guerrier, et al., *Proc. Natl. Acad. Sci USA*, 1997;94:8468-8472; White, et al., *Antimicrob. Agent Chem.*, 1997, 41:2699-2704; Rom, et al., *Am. J. Res. Crit. Care. Med.*, 1997, 156:1993-1998; Nielson, et al., *Nat. Biotech.*, 1998, 16:355-358), and in particular, with enterococci or more specifically, with vancomycin-resistant enterococci, have yet to be reported. Although data have been published on the use 10 of anti-resistance determinant genetic elements in other microorganisms (e.g. *Escherichia coli* and *Staphylococcus aureas*) there are yet no published data on the use of this technology for vancomycin-resistant *Enterococcus* (Takada-Guerrier, et al., *Proc. Natl. Acad. Sci USA*, 1997, 94:8468-8472; White, et al., *Antimicrob. Agent Chem.*, 1997, 41:2699-2704).

15

Summary of the Invention

In the most basic of terms, a successful strategy against antibiotic resistant enterococci would require either (1) the retention of antimicrobial activity despite the presence of the drug 20 resistance mechanism (i.e. a lack of cross-resistance), or (2) the perturbation of the antibiotic resistance mechanism itself and, as a consequence, reversion of the bacterium to a drug-susceptible phenotype. In our studies, the unique approach taken towards the treatment of vancomycin-resistant enterococci is of the latter type. Herein, we present a gene-based strategy which targets a key vancomycin resistance determinant and results in the restoration of vancomycin susceptibility in previously glycopeptide-resistant enterococci.

Thus, the invention overcomes the above-noted and other problems of the prior art by 25 providing methods and related compositions for reducing antibiotic resistance in vancomycin resistant microorganisms. More particularly, the present invention provides a gene cassette comprised of the *vanH* promoter and a single copy of a *vanA* antisense gene in an enterococcal shuttle vector. Using this invention, we have demonstrated an ability to increase the vancomycin susceptibility in previously resistant *Enterococcus faecalis*.

According to one aspect of the invention, a method for reducing vancomycin 30 resistance in a vancomycin-resistant organism is provided. The method involves introducing into the organism at least one "anti-sense vancomycin resistance molecule" under conditions to inhibit expression of a vancomycin resistance gene. By "inhibit expression" it is meant to

-5-

inhibit replication, transcription, and/or translation of a vancomycin gene since inhibition of any of these processes results in the inhibition of expression of a protein encoded by a vancomycin gene. Exemplary vancomycin-resistant organisms include the Gram-positive bacteria *Enterococcus faecium* and *Enterococcus faecalis* and other bacteria to which these organisms have the potential of transferring resistance determinants, given that VanA is a transferable form of resistance and that it could be transferred to other clinically significant pathogens such as *Streptococcus Pneumococcus*, and *Staphylococcus*. (See, e.g., Brisson-Noel A., et al., *J. Bacteriol.*, 1988, 170:1739-1745).

Preferably, the vancomycin resistant organism is a Gram-positive bacteria and, more preferably, the organism is an *Enterococcus*.

Vancomycin resistance can take a variety of forms depending upon the nature of the gene cluster which mediates the resistance phenotype. Thus, exemplary vancomycin resistant organisms of the invention may exhibit one or more of the following phenotypes: VanA resistance, VanB resistance, VanC resistance, and VanD resistance. VanA resistance is mediated by a gene cluster which includes seven genes: *vanR* (SEQ ID NO:18), *vanS* (SEQ ID NO:19), *vanH* (SEQ ID NO:20), *vanA* (SEQ ID NO:21), *vanX* (SEQ ID NO:22), *vanY* (SEQ ID NO:23), and *vanZ* (SEQ ID NO:24).

In a preferred embodiment in which the vancomycin resistant organism carries a VanA genotype, the antisense vancomycin resistance molecule is selected from the group consisting of antisense molecules which hybridize under stringent conditions to these target genes or to conserved regions of these target genes (e.g., SEQ ID NOS: 5, 6, 7, 8, 9, and 10). As used herein, such antisense molecules to these target genes are referred to as *vanR* antisense molecules, *vanS* anti-sense molecules, *vanH* anti-sense molecules, *vanA* anti-sense molecules, *vanX* anti-sense molecules, *vanY* anti-sense molecules, and *vanZ* anti-sense molecules, respectively. In a particularly preferred embodiment, the organism is a VanA type, and the anti-sense vancomycin resistance molecule hybridizes under stringent conditions to the *vanA* target gene (SEQ ID NO:21), or to a conserved region of the *vanA* gene (e.g., SEQ ID NOS: 7, and 8). In a further preferred embodiment, the organism is a VanA type, and the anti-sense vancomycin resistance molecule hybridizes under stringent conditions to the *vanX* target gene (SEQ ID NO:22), or to a conserved region of the *vanX* gene (e.g., SEQ ID NO:10).

Additionally or alternatively, the vancomycin resistant organism can be a VanB, VanC, and/or VanD type organism and the anti-sense vancomycin resistance molecule is a

-6-

nucleic acid molecule which hybridizes under stringent conditions to these target genes (SEQ ID NO:2 is the vanB gene cluster sequence; SEQ ID NO:3 is the vanC gene sequence; SEQ ID NO:4 is the vanD gene cluster sequence) or to conserved regions of these target genes (e.g., SEQ ID NOS: 11, 12, and 13).

5 In general, the antisense molecules which hybridize to a conserved region of a target vancomycin resistance gene contain from about 18 to about 1500 nucleotides, more preferably from about 10 to about 30 nucleotides, and most preferably from about 20 to about 30 nucleotides.

10 In general, the anti-sense vancomycin resistance molecules are introduced to the organism by contacting the vancomycin resistant organism with at least one cassette (typically contained in a vector) comprising one or more "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes. In general, the vector comprises an expression cassette which permits expression of the anti-sense vancomycin resistance molecules in the 15 organism. The preferred vectors are selected from the group consisting of: an enterococcal shuttle vector (e.g., see the Examples), an enterococcal bacteriophage (Merril CR, et al., *Proc Natl Acad Sci USA*, 1996, 93:3188-92); the nucleic acid portion of a peptide nucleic acid molecule (Good L, et al., *Nat Biotechnol*, 1998; 16:355-8); an enterococcal conjugative transposon or pheromone-responsive plasmid (Murray BE, *Emerg Infect Dis*, 1998, 4:37-47).

20 In certain embodiments such as those described in detail in the Examples, the cassette contains one or more copies of a *vanA* antisense molecule operatively coupled to a promoter, preferably, the same inducible promoter which drives expression of the *vanH*, *vanA*, and *vanX* resistance determinant, e.g., a *VanR*-responsive promoter such as the *vanH* promoter. As used herein, a *VanR*-responsive refers to a promoter which activates transcription in 25 response to binding of a phosphorylated *VanR* protein.

30 Preferably, the *VanR*-responsive promoter is a *vanH* promoter (P_{vanH}) or a *vanR* promoter (P_{vanR}), each of which directs transcription of the genes of the vancomycin resistance operon found in several species. These *VanR*-responsive promoters activate transcription in response to binding of an activated *VanR* protein. These promoters include, in addition to the *VanR* binding sites, all other sequences required for efficient transcriptional activation of the gene or genes located downstream of the promoters. In general, these *VanR*-responsive promoters (P_{vanH} , P_{vanR}) include the 60 nucleotides immediately upstream (nucleotides -60 to -1) of the genes encoding a *VanR* protein or a *VanR* protein, which

-7-

sequences include a *VanR* binding site, and other sites which contribute to efficient *VanR*-responsive activation of gene transcription.

Other *VanR*-responsive promoters can be used to effect transcription of protein coding sequences. For example, alternative *VanR*-responsive promoters can be identified by 5 searching databases of bacterial nucleotide sequences for sequences which have *VanR* binding sites in proximity to sites which contribute to efficient bacterial transcriptional activation, e.g. a consensus binding site for bacterial DNA polymerase. Such sites are well-known to one of ordinary skill in the art. *VanR*-responsive promoters can also be identified by genetic screening and cloning protocols that are standard in the art, as described in Sambrook. 10 Further, non-natural *VanR* promoters can be prepared by combining a *VanR* binding site with the other nucleotide sequences which contribute to efficient bacterial transcriptional activity. Such synthetic or non-natural *VanR*-responsive promoters can be synthesized directly by chemical means, such as by use of an automated DNA synthesizer.

In an analogous manner, other embodiments can be prepared in which the expression 15 cassette contains one or more copies of a different vancomycin resistance antisense molecule operatively coupled to a promoter which drives expression of the targeted antisense gene.

In yet another aspect of the invention, an alternative method for reducing vancomycin 20 resistance is provided. According to this aspect of the invention, the method involves enhancing expression of a *VanR*-responsive promoter, such as a *vanH* promoter, in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism. As used herein, a "vancomycin resistance gene of the organism" refers to the gene 25 in its native configuration contained within the genome of the organism, i.e., not isolated from the organism.

25 In certain preferred embodiments, the *vanH* promoter is operatively coupled to an antisense vancomycin resistance molecule, such as a *vanA* anti-sense molecule. More preferably, the *vanH* promoter (alone or operatively coupled to an antisense vancomycin resistance molecule) is contained in a cassette. Typically, the cassette is contained in a vector to facilitate transport into and out of the resistant organism. In a particularly preferred 30 embodiment, the vector is an *enterococcal* vector and enhancing expression of the *vanH* promoter involves introducing the vector into the organism. Although not wishing to be bound to a particular theory or mechanism, it is believed that introducing the vector into the

-8-

organism results in expression of an amount of the *vanH* promoter sufficient that is sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism. In further preferred embodiments, the *VanR*-responsive promoter, such as a *vanH* promoter is co-administered into the organism together with an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter.

According to still other aspects of the invention, compositions for use in accordance with the methods of the invention are provided. In certain embodiments, the compositions of the invention are isolated nucleic acids that hybridize under stringent conditions to a targeted vancomycin gene or a conserved region thereof, such as described in more detail below. In a particularly preferred embodiment, the isolated nucleic acid is vancomycin resistance gene sequence which has been cloned in the opposite direction (see, e.g., the Examples). Exemplary target genes and conserved regions thereof include the genes which are contained in the VanA resistance gene cluster (GenBank Accession No. M97297, SEQ ID NO:1), the VanB resistance gene cluster (GenBank Accession No. U35369, SEQ ID NO:2), the VanC resistance gene cluster (GenBank Accession No. L29638, SEQ ID NO:3), and the VanD resistance gene cluster (GenBank Accession No. AF130997, SEQ ID NO:4). The location of the individual genes in each gene cluster is set forth in each GenBank listing. Thus, the anti-sense molecules of the invention have sequences which are complementary, and therefore capable of hybridizing to the target genes identified herein, as well as to conserved and/or unique regions of these genes (e.g., by using routine skill to search nucleic acid databases such as GenBank to identify regions of the vancomycin resistance genes which are conserved and/or which are unique). In certain preferred embodiments, the anti-sense molecules of the invention hybridize to regions of the target gene which encode an active site or other which encodes an active site or other functional portion of the encoded protein (e.g., the active site of the ligase encoded by the *vanA* gene). Using such techniques, Applicants have identified the following nucleotide regions of representative target genes to which the anti-sense molecules can be designed to hybridize (i.e., the anti-sense molecules have complementary nucleotide sequences to the target genes or the selected regions).

SUMMARY TABLE

30	<u>SEQ ID NO</u>	<u>GENE/ACC NO</u>	<u>NUCLEOTIDE NOS</u>	<u>TARGETED SEQ NO</u>
	5	<i>vanS</i> /M97297	5657 to 5684	5'-ggggcgccggacttggatggcgattg-3'
	6	<i>vanR</i> /M97297	4258 to 4287	5'ggcgccggatgattataacgaagcccttt-3'

-9-

7	<i>vanA</i> /M97297	7719 to 7736	5'-cgagccggaaaaaggctc-3'
8	<i>vanA</i> /M97297	7339 to 7358	5'-ggctgcgatattcaaagctc-3'
9	<i>vanH</i> /M97297	6033 to 6059	5'-attactgttatggatgtgagcaggat-3'
10	<i>vanX</i> /M97297	8343 to 8368	5'-gtggcttcaaaatcaagccatagccg-3'
11	VanB/U35369	5708 to 5725	5'-cgagccggaaaaaggctc-3'
12	VanB/U35369	5328 to 5347	5'-ggctgcgatattcaaagctc-3'
13	VanD/AF130997	4443 to 4462	5'-ggctgcgatattcaaagctc-3'

It will be understood that anti-sense molecules which contain a few nucleotide residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) which hybridize to either side of the above-identified conserved nucleotide regions are embraced within the meaning of the anti-sense molecules disclosed and claimed herein for use in accordance with the methods of the invention.

According to still other aspects of the invention, cassettes containing the isolated nucleic acids of the invention, as well as vectors containing such nucleic acids and/or cassettes, also are provided. Preferably the cassettes further comprise a vancomycin-inducible promoter (e.g., a *VanR*-responsive promoter such as a *vanH* promoter) operatively coupled to one or more isolated nucleic acid molecules of the invention. In still other embodiments, isolated vancomycin resistant organisms containing any of the foregoing isolated nucleic acids, cassettes and/or vectors also are provided.

These and other embodiments and utilities of the invention will become more apparent in reference to the following drawings and detailed description of the preferred embodiments.

All references are incorporated in their entirety herein by reference.

Brief Description of the Sequences

SEQ ID NO:1 -- The nucleic acid encoding the VanA resistance gene cluster of *Enterococcus faecium*. GenBank accession number M97297.

SEQ ID NO:2 -- The nucleic acid encoding the VanB resistance gene cluster of *Enterococcus faecalis*. GenBank accession number U35369.

SEQ ID NO:3 -- The nucleic acid encoding the VanC resistance gene cluster of *Enterococcus casseliflavus*. GenBank accession number L29638.

SEQ ID NO:4 -- The nucleic acid encoding the VanD resistance gene cluster of *Enterococcus faecium*. GenBank accession number AF130997.

SEQ ID NO:5 -- A conserved nucleic acid region of the *vanS* gene of the VanA gene cluster.

-10-

SEQ ID NO:6 -- A conserved nucleic acid region of the *vanR* gene of the VanA gene cluster.

SEQ ID NO:7 -- A conserved nucleic acid region of the *vanA* gene of the VanA gene cluster (nucleotides 7719 to 7736).

5 SEQ ID NO:8 -- A conserved nucleic acid region of the *vanA* gene of the VanA gene cluster (nucleotides 7339 to 7358).

SEQ ID NO:9 -- A conserved nucleic acid region of the *vanH* gene of the VanA gene cluster.

10 SEQ ID NO:10 -- A conserved nucleic acid region of the *vanX* gene of the VanA gene cluster.

SEQ ID NO:11 -- A conserved nucleic acid region of the *vanB* gene cluster (nucleotides 5708 to 5725).

SEQ ID NO:12 -- A conserved nucleic acid region of the *vanB* gene cluster (nucleotides 5328 to 5347).

15 SEQ ID NO:13 -- A conserved nucleic acid region of the *vanD* gene cluster.

SEQ ID NO:14 -- A 5' -PCR primer oligonucleotide sequence for the *vanH* promoter, used in conjunction with the primer of SEQ ID NO:15.

SEQ ID NO:15 -- A 3' -PCR primer oligonucleotide sequence for the *vanH* promoter, used in conjunction with the primer of SEQ ID NO:14.

20 SEQ ID NO:16 -- A 5' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:17.

SEQ ID NO:17 -- A 3' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:16.

25 SEQ ID NO:18 -- The nucleotide sequence of the *vanR* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:19 -- The nucleotide sequence of the *vanS* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:20 -- The nucleotide sequence of the *vanH* gene of the VanA gene cluster (SEQ ID NO:1).

30 SEQ ID NO:21 -- The nucleotide sequence of the *vanA* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:22 -- The nucleotide sequence of the *vanX* gene of the VanA gene cluster (SEQ ID NO:1).

-11-

SEQ ID NO:23 -- The nucleotide sequence of the *vanY* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:24 -- The nucleotide sequence of the *vanZ* gene of the VanA gene cluster (SEQ ID NO:1).

5 SEQ ID NO:25 -- A 3' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:16.

SEQ ID NO:26 -- The nucleotide sequence of the *vanRB* gene of the VanB gene cluster (SEQ ID NO:2).

10 SEQ ID NO:27 -- The nucleotide sequence of the *vanSB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:28 -- The nucleotide sequence of the *vanYB* gene of the VanB gene cluster (SEQ ID NO:2).

15 SEQ ID NO:29 -- The nucleotide sequence of the *vanHB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:30 -- The nucleotide sequence of the *vanB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:31 -- The nucleotide sequence of the *vanXB* gene of the VanB gene cluster (SEQ ID NO:2).

20 SEQ ID NO:32 -- The nucleotide sequence of the *vanW* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:33 -- The nucleotide sequence of the *vanC-2* gene of the VanC gene cluster (SEQ ID NO:3).

25 SEQ ID NO:34 -- The nucleotide sequence of the *vanRD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:35 -- The nucleotide sequence of the *vanSD* gene of the VanD gene cluster (SEQ ID NO:4).

30 SEQ ID NO:36 -- The nucleotide sequence of the *vanYD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:37 -- The nucleotide sequence of the *vanHD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:38 -- The nucleotide sequence of the *vanD* gene of the VanD gene cluster (SEQ ID NO:4).

-12-

SEQ ID NO:39 -- The nucleotide sequence of the *vanXD* gene of the VanD gene cluster (SEQ ID NO:4).

Brief Description of the Drawings

5 **Figure 1.** A schematic showing the organization of genes in the VanA vancomycin resistance operon.

10 **Figure 2.** Schematic maps of the shuttle vectors and relevant cloning sites; Fig. 2A shows the parent vector, pAM401; Fig. 2B shows the restriction sites for the *vanH* promoter insertion into pAM401; Fig. 2C shows the restriction sites for the *vanA* antisense insertion into *vanH* promoter/pAM401 construct.

15 **Figure 3.** A schematic showing the proposed nucleic acid binding decoy mechanism with the introduction of a shuttle vector carrying the *vanH* promoter alone.

20 **Figure 4.** A schematic of the proposed mechanism-of-action of the pAM401-*vanH* promoter-*vanA* antisense recombinant shuttle vector.

Detailed Description of the Invention

25 While vancomycin has been the mainstay of treatment for beta-lactam antibiotic-resistant enterococci, the increasing prevalence of vancomycin-resistant enterococci has prompted a continued search for new therapeutic approaches. In eukaryotic and prokaryotic systems, gene transfer has been used to define molecular pathogenesis as well as applied towards therapeutic ends. The elucidation of the genetic basis for vancomycin resistance has uncovered potential targets for a unique anti-drug resistance gene-based strategy. Particularly, the preferred embodiments of the present invention consist of a gene cassette comprised of the enterococcal *vanH* promoter and a single copy of a *vanA* antisense gene in the shuttle vector, pAM401. Using this invention, we have demonstrated the ability to increase the vancomycin susceptibility of a vancomycin-resistant *Enterococcus faecalis* by up to 32-fold.

30 According to one aspect of the invention, a method for reducing vancomycin resistance in a vancomycin-resistant organism is provided. The method involves introducing into the organism at least one "anti-sense vancomycin resistance molecule" under conditions to inhibit expression of a vancomycin resistance gene.

As used herein, "reducing vancomycin resistance" refers to enhancing the susceptibility of a vancomycin resistant organism to vancomycin to a statistically significant extent. In the embodiments illustrated in the Examples, the methods of the invention have

-13-

been used to increase the vancomycin susceptibility of a vancomycin-resistant *Enterococcus faecalis* by at least about 16-fold and up to about 32-fold compared to organisms which have not been so treated. These results demonstrate the utility of the invention for reducing vancomycin resistance in the particular organisms tested, as well as the feasibility of using the 5 methods of the invention for treating other types of glycopeptide-resistant bacteria (e.g., VanB, VanC, and VanD type bacteria).

According to certain aspects of the invention, the methods involve inhibiting expression of a vancomycin resistance gene. As used herein, "inhibit expression" refers to inhibiting (i.e., reducing to a detectable extent) replication, transcription, and/or translation of 10 a vancomycin gene since inhibition of any of these processes results in the inhibition of expression of a protein encoded by a vancomycin gene. Exemplary vancomycin-resistant organisms include the Gram-positive bacteria *Enterococcus faecium* and *Enterococcus faecalis* and other bacteria to which these organisms have the potential of transferring 15 resistance determinants, given that VanA is a transferable form of resistance and that it could be transferred to other clinically significant pathogens such as *Streptococcus* species, *Pneumococcus*, and *Staphylococcus* species. (See, e.g., Brisson-Noel A. Arthur, M. Courvalin P., "Evidence for natural gene transfer from Gram-positive cocci to *Escherichia coli*," *J. Bacteriol.* 170:1739-1745, 1988).

Preferably, the vancomycin resistant organism is a Gram-positive bacteria and, more 20 preferably, the organism is an *Enterococcus*.

Vancomycin resistance can take a variety of forms depending upon the nature of the gene(s) which mediates the resistance phenotype. Thus, exemplary vancomycin resistant organisms of the invention may exhibit one or more of the following phenotypes: VanA resistance, VanB resistance, VanC resistance, and VanD resistance.

VanA resistance is mediated by a gene cluster (SEQ ID NO:1) which includes seven 25 genes: *vanR* (SEQ ID NO:18), *vanS* (SEQ ID NO:19), *vanH* (SEQ ID NO:20), *vanA* (SEQ ID NO:21), *vanX* (SEQ ID NO:22), *vanY* (SEQ ID NO:23), and *vanZ* (SEQ ID NO:24), as described in GenBank Accession No. M97297 (SEQ ID NO:1). VanB resistance is mediated by a gene cluster which includes seven genes: *vanRB* (SEQ ID NO:26), *vanSB* (SEQ ID 30 NO:27), *vanYB* (SEQ ID NO:28), *vanHB* (SEQ ID NO:29), *vanB* (SEQ ID NO:30), *vanXB* (SEQ ID NO:31), and *vanW* (SEQ ID NO:32), as described in GenBank Accession No. U35369 (SEQ ID NO:2); VanC resistance is mediated by a *vanC-2* gene (SEQ ID NO:33), as described in GenBank Accession No. L29638 (SEQ ID NO:3); VanD resistance is mediated

-14-

by a gene cluster which includes at least six genes: *vanRD* (SEQ ID NO:34), *vanSD* (SEQ ID NO:35), *vanYD* (SEQ ID NO:36), *vanHD* (SEQ ID NO:37), *vanD* (SEQ ID NO:38), and *vanXD* (SEQ ID NO:39), as described in GenBank Accession No. AF130997 (SEQ ID NO:4). Although the Examples illustrate the application of the invention for treating *vanA* resistance, it is to be understood that the invention can be tailored to treating one or more types of antibiotic resistance to a vancomycin antibiotic by selecting antisense molecules and/or appropriate promoters which can be used to reduce expression of the resistance genes in the targeted organism.

In a preferred embodiment in which the vancomycin resistant organism is a VanA organism, the antisense vancomycin resistance molecule is selected from the group consisting of antisense molecules which hybridize under stringent conditions to these target genes or to conserved, unique, or functionally important regions of these target genes as described above. As used herein, such antisense molecules to these target genes are referred to as *vanA* anti-sense molecules, *vanR* antisense molecules, *vanS* anti-sense molecules, *vanH* anti-sense molecules, *vanX* anti-sense molecules, *vanY* anti-sense molecules, and *vanZ* anti-sense molecules, respectively. In a particularly preferred embodiment, the organism carries a VanA phenotype and the anti-sense vancomycin resistance molecule hybridizes under physiological conditions to the *vanA* target gene or to a conserved region of the *vanA* gene.

Additionally or alternatively, the vancomycin-resistant organism can be a VanB, VanC, and/or VanD resistant organism and the anti-sense vancomycin resistance molecule is selected which hybridizes under stringent conditions to these target genes (SEQ ID NO:2 is the VanB gene cluster sequence; SEQ ID NO:3 is the VanC gene sequence; SEQ ID NO:4 is the VanD gene cluster sequence) or to conserved regions of these target genes. In general, the antisense molecules are isolated molecules which hybridize to a conserved region of a target vancomycin resistance gene contain from about 18 to about 1500 nucleotides, more preferably from about 10 to about 30 nucleotides, and most preferably, from about 20 to about 30 nucleotides.

The nucleic acid molecules described herein preferably are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which

-15-

5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

10 As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to a messenger RNA (mRNA) transcript of that gene and, thereby, inhibits the transcription of that gene and/or the
15 translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which
20 comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under the physiological conditions of the target organism, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding the vancomycin resistance proteins, or upon allelic or homologous
25 genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified
30 oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides. (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases.

-16-

Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 1994, 14(5):439-457) and at which proteins are not expected to bind. Finally, although the listed sequences may include cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a vancomycin resistance gene. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding vancomycin resistance proteins. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

Exemplary U.S. patents which describe and claim antisense molecules for reducing gene expression include U.S. Patent Nos. 5,734,039; 5,783,683; 5,859,229; 5,858,987; 5,919,677; and 5,916,807; the entire contents of which patents are incorporated in their entirety herein by reference.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its oligonucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage rather than a phosphodiester linkage between the 5' end of one oligonucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not

-17-

normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

5 The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-
10 alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding vancomycin resistance polypeptides, together with acceptable carriers to deliver these molecules into the
15 target organism.

The compositions of the invention may be administered as part of a pharmaceutical composition to a mammal (e.g., humans, domestic animals, such as dogs, cats, livestock, such as horses, sheep, cows, pigs) hosting a vancomycin resistant organism. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the rout of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.
20
25

The compositions of the invention also may be introduced into vancomycin resistant organisms which is *ex vivo*, i.e., not contained within a mammal. For example, the applications of such compositions include both treatment of vancomycin-resistant enterococci or other clinically significant pathogen infections and colonization including, for example:
30 (1) *ex vivo* eradication of vancomycin-resistant enterococci from frequently colonized settings

-18-

(e.g., intensive care units, hemodialysis units, chronic care facilities); (2) *in vivo* clearance of vancomycin-resistant enterococci from colonized gastrointestinal or genitourinary tracts of human and animal subjects; and (3) primary or adjuvant therapy for vancomycin-resistant enterococcal infections. In certain embodiments, antisense oligonucleotides (e.g., a synthetic antisense DNA strand) are used as a means for delivering this motif into bacteria by delivering the genes which code for antisense RNA (e.g., by conjugation, transformation, or transduction with bacteriophage). Accordingly, the antisense motif and other anti-resistance determinant genetic elements of the invention (e.g., nucleic acid binding decoys, transdominant mutants, suicide genes, ribozymes etc.) may be introduced into enterococci via transconjugation or via recombinant bacteriophage.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host organism. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome or host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and

-19-

expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a vancomycin polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host bacterium.

-20-

The vancomycin resistance operons of a targeted organism include, e.g., the naturally occurring operon of *Enterococcus faecium*, or such operons which are substantially identical thereto, e.g., homologs of the vancomycin resistance operon of *Enterococcus faecium* from other species, functionally equivalent variant of the vancomycin resistance operon containing variants of the genes which constitute the naturally occurring operon. Such variants may be sequence variants, e.g., containing conservative substitutions of amino acids and the like as defined herein, or may be different genes which have the same or a similar function as one of the genes found in the naturally-occurring vancomycin operon. For example, the *ddlB* gene of *E. coli* encodes a protein that exhibits similar properties of the VanA protein as discussed below. Thus, a preferred vancomycin resistance operon of a targeted organism typically includes a *vanH* gene, a *ddlB* gene and a *vanX* gene.

The VanA protein product has two activities: a D-Ala-D-hydroxybutyrate depsipeptide ligase activity (Bugg et al., *Biochemistry* 30:2017-2021, 1991). VanA shares 28% amino acid identity with an *E. coli* enzyme, DdlB, which is a D-Ala-D-Ala dipeptide ligase. Two point mutants of DdlB recently have been reported that exhibit depsipeptide ligase activity (S150A and Y126F; Shi & Walsh, *Biochemistry* 34:2768-2776, 1995; Park et al., *Biochemistry*, 1996, *in press*). Thus, these mutants appear to be functional homologs of VanA. Other functional homologs include, for example, genes encoding a VanA or DdlB protein that are present in other vancomycin operons, including such genes present in other species which encode vancomycin resistance. For example, other vancomycin resistant strains of bacteria (i.e., not *Enterococci* which have a VanA operon) have modified Ddl proteins which serve to make depsipeptide termini directly. Non-VanA vancomycin resistance operons such as the VanB vancomycin resistance operon, contain functionally equivalent VanA homologs. Other functional homologs, either natural or non-natural, are also embraced by the invention.

In general, the anti-sense vancomycin resistance molecules are introduced to the organism by contacting the vancomycin resistant organism with at least one cassette, preferably contained in a vector, which cassette comprises one or more "anti-sense vancomycin resistance molecules" operably coupled to a promoter (e.g., a *VanR* response promoter). The cassette is contacted with the organism under conditions which allow the cassette and/or vector to enter the organism and inhibit expression of one or more vancomycin resistance genes. Typically, the vector comprises an expression cassette which permits expression of the anti-sense vancomycin resistance molecules in the organism. The preferred vectors are selected from the group consisting of: an enterococcal shuttle vector

-21-

(e.g., see the Examples), an enterococcal bacteriophage (Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S, "Long-Circulating Bacteriophage as Antibacterial Agents," *Proc Natl Acad Sci USA*, 1996; 93:3188-92); the nucleic acid portion of a peptide nucleic acid molecule (Good L, Nielsen PE, "Antisense Inhibition of Gene Expression in Bacteria by PNA Targeting To mRNA," *Nat Biotechnol* 1998; 16:355-8); an enterococcal conjugative transposon or pheromone-responsive plasmid (Murray BE, "Diversity Among Multidrug-Resistant Enterococci," *Emerg Infect Dis* 1998; 4:37-47).

In certain embodiments such as those described in detail in the Examples, the cassette contains one or more copies of a *vanA* antisense molecule, e.g., in tandem, operatively coupled to a promoter, preferably, the same inducible promoter which drives expression of the *vanA* resistance determinant, e.g., a *VanR*-responsive promoter such as the *vanH* promoter. As used herein, a *VanR*-responsive refers to a promoter which activates transcription in response to binding of an activated *VanR* protein. These promoters include, in addition to the *VanR* binding site, all other sequences required for efficient transcriptional activation of the gene or genes located downstream of the promoters. In an analogous manner, other embodiments can be prepared in which the expression cassette contains one or more copies of a different vancomycin antisense molecule operatively coupled to a promoter which drives expression of the targeted antisense gene.

In yet another aspect of the invention, an alternative method for reducing vancomycin resistance is provided. According to this aspect of the invention, the method involves enhancing expression of a *VanR*-responsive promoter (e.g., a *vanH* promoter) in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism. As used herein, a "vancomycin resistance gene of the organism" refers to the gene in its native configuration contained within the genome of the organism, i.e., not isolated from the organism or attached to nucleic acid which is not contained within the genome of the organism.

In certain preferred embodiments, the *VanR*-responsive promoter is operatively coupled to an antisense vancomycin resistance molecule, such as a *vanA* anti-sense molecule. More preferably, the *VanR*-responsive promoter (alone or operatively coupled to an antisense vancomycin resistance molecule) is contained in a cassette. Typically, the cassette is contained in a vector to facilitate transport into and out of the resistant organism. In a particularly preferred embodiment, the vector is an *enterococcal* vector and enhancing

-22-

expression of the *VanR*-responsive promoter involves introducing the vector into the organism. An exemplary cassette, vector and process for introducing the cassette into a vancomycin resistant organism and representative experimental evidence showing the efficacy of the claimed methods for reducing antibiotic resistance in a vancomycin resistant organism are described in the Examples.

Although not wishing to be bound to a particular theory or mechanism, it is believed that introducing the vector into the organism results in expression of an amount of the *VanR*-responsive promoter (e.g., a *vanH* promoter) that is sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism by competitively sequestering the phosphorylated *VanR* protein.

According to still other aspects of the invention, compositions for use in accordance with the methods of the invention are provided. In certain embodiments, the compositions of the invention are isolated nucleic acids that hybridize under stringent conditions to a targeted vancomycin gene or a conserved region thereof, such as described in more detail below. In a particularly preferred embodiment, the isolated nucleic acid is vancomycin resistance gene sequence which has been cloned in the opposite direction (see, e.g., the Examples). Exemplary target genes and conserved regions thereof include the genes which are contained in the *vanA* resistance gene cluster (GenBank Accession No. M97297, SEQ ID NO:1), the *vanB* resistance gene cluster (GenBank Accession No. U35369, SEQ ID NO:2), the *vanC* resistance gene (GenBank Accession No. L29638, SEQ ID NO:3), and the *vanD* resistance gene cluster (GenBank Accession No. AF130997, SEQ ID NO:4). The location of the individual genes in each gene cluster is set forth in each GenBank listing. Thus, the anti-sense molecules of the invention have sequences which are complementary, and therefore capable of hybridizing to the target genes identified herein, as well as to conserved and/or unique regions of these genes (e.g., by using routine skill to search nucleic acid databases such as GenBank to identify regions of the vancomycin resistance genes which are conserved and/or which are unique). In certain preferred embodiments, the anti-sense molecules of the invention hybridize to regions of the target gene which encode an active site or other which encodes an active site or other functional portion of the encoded protein (e.g., the active site of the ligase encoded by the *vanA* gene). Using such techniques, Applicants have identified the following nucleotide regions of representative target genes to which the anti-sense molecules can be designed to hybridize (i.e., the anti-sense molecules have complementary nucleotide sequences to the target genes or the selected regions).

-23-

SUMMARY TABLE

<u>SEQ ID NO</u>	<u>GENE/ACC NO</u>	<u>NUCLEOTIDE NOS</u>	<u>TARGETED SEQ NO</u>
5	<i>vanS</i> /M97297	5657 to 5684	5'-ggggcgccggacttggatggcgattg-3'
6	<i>vanR</i> /M97297	4258 to 4287	5'ggcgccggatgattataacgaagccctt-3'
7	<i>vanA</i> /M97297	7719 to 7736	5'-cgagccggaaaaggctc-3'
8	<i>vanA</i> /M97297	7339 to 7358	5'-ggctgcgatattcaaagctc-3'
9	<i>vanH</i> /M97297	6033 to 6059	5'-attactgttatggatgtgaggat-3'
10	<i>vanX</i> /M97297	8343 to 8368	5'-gtggcttcaaaatcaagccatagccg-3'
11	<i>vanB</i> /U35369	5708 to 5725	5'-cgagccggaaaaggctc-3'
12	<i>vanB</i> /U35369	5328 to 5347	5'-ggctgcgatattcaaagctc-3'
13	<i>vanD</i> /AF130997	4443 to 4462	5'-ggctgcgatattcaaagctc-3'

15 It will be understood that anti-sense molecules which contain a few nucleotide residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) which hybridize to either side of the above-identified conserved nucleotide regions are embraced within the meaning of the anti-sense molecules disclosed and claimed herein for use in accordance with the methods of the invention.

20 The term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄ (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at 25 65°C.

30 There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of nucleic acids encoding proteins of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

-24-

According to still other aspects of the invention, cassettes containing the isolated nucleic acids of the invention, as well as vectors containing such nucleic acids and/or cassettes, also are provided. Preferably the cassettes further comprise a vancomycin-inducible promoter (e.g., a *VanR*-responsive promoter such as a *vanH* promoter) operatively coupled to one or more isolated nucleic acid molecules of the invention. In still other embodiments, isolated vancomycin resistant organisms containing any of the foregoing isolated nucleic acids, cassettes and/or vectors also are provided.

"Co-administering," as used herein, refers to administering simultaneously two or more compounds (constructs) of the invention (e.g., the *VanR*-responsive promoter, such as a *vanH* promoter, and an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter), as an admixture in a single composition, or sequentially, close enough in time so that the compounds may exert an additive or even synergistic effect, i.e., on reducing vancomycin resistance.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

Examples

Plasmids

The parent shuttle plasmid used in the test vector constructs was pAM401 (American Type Culture Collection, Rockville, MD) (Wirth, et al., *J. Bacteriol.*, 1986;165:831-836). This plasmid is a high copy shuttle vector containing both Gram-negative bacillary (*Escherichia coli*) and enterococcal (*Enterococcus faecalis*) elements necessary for replication in these two bacterial types (Figure 2). To aid in selection of appropriately transformed clones, this plasmid also contains tetracycline and chloramphenicol resistance genes.

The cloning vector, pAMP1 (Gibco BRL, Rockville, MD), was also employed for the cloning of polymerase chain reaction-amplified fragments.

Construction of Recombinant Enterococcal Shuttle Vectors

The structures of the recombinant pAM401 shuttle vectors, including their pertinent restriction sites and vector constituents, are outlined in Figure 2 (Wirth, et al., *J Bacteriol.*, 1986, 165:831-6). To construct a pAM401 shuttle vector containing the *vanH* promoter alone, *vanHP* was removed from pAMP1-*vanHP* using Xba I and Sal I restriction enzymes and ligated into pAM401 pre-digested with the same enzymes with the resultant pAM401-*vanHP*

-25-

shuttle vector (Figure 2). To produce the pAM401-*vanHP-vanA* antisense, *vanA* was digested out of pAMP1-*vanA* antisense with Xho I and Sal I and cloned into the Sal I site in pAM401-*vanHP* in the anti-coding direction.

Bacterial Strains

Vancomycin-resistant *Enterococcus faecalis* strains, designated A407 and A403, were VanA phenotype clinical isolates obtained from E. Cercenada (Hospital General Gregorio Marañón, Madrid, Spain). A1221 is a VanA strain of *Enterococcus faecium* resulting from the transconjugation with a VanA strain of *Enterococcus faecalis* (A312) obtained from F. Tenover (Centers for Disease Control, Atlanta, GA). These strains were identified as *Enterococcus faecalis* or *faecium* by the use of API-Rapid Strep Strips (bioMerieux Vitex, Inc., Hazelwood, MO). The presence of the *vanA* genotype was confirmed by DNA probe analysis as previously described (Eliopoulos, et al., *Antimicrob. Agents Chemother.*, 1998, 42:1088-92).

Vancomycin susceptibilities were determined by the National Committee for Clinical Laboratory Standards agar dilution method (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A4. Wayne, PA: NCCCLS, 1997). Commercially prepared competent DH5-alpha *Escherichia coli* (Gibco BRL, Rockville, MD) were also used in the cloning and sub-cloning of the vectors via a standard transformation protocol (Sambrook, et al., In:*Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 1989; 1.74).

Antibiotics, Culture Media, Cloning Reagents

Vancomycin and other antimicrobial agents were purchased from Sigma (St. Louis, MO). Restriction and modifying enzymes were obtained from Promega (Madison, WI) and New England BioLabs, Inc. (Beverly, MA). *Escherichia coli* were grown in Luria-Bertani medium and enterococci were grown on Mueller-Hinton or Blood-agar medium. Plasmid preparations were performed using Promega Wizard DNA Purification systems (Madison, WI).

vanH Promoter and *vanA* Antisense Construction

An approximate 450 base-pair fragment containing the *vanH* promoter - previously described to be necessary for expression of *vanH*, -*A*, and -*X* - was amplified using genomic DNA from a known strain of VanA strain *Enterococcus faecium* (A1221) as a template (Arthur, et al., *J. Bacter.*, 1992, 174:2582-2591). 5' and 3' primers were synthesized by

-26-

Gibco BRL (Rockville, MD). The primer sequences for the respective 5' and 3' *vanH* promoter primers as follows:

5'-CUA CUA CUA CUA CGA ATT CAA GAA CAC TGG-3' (SEQ ID NO:14)

5'-CAU CAU CAU CCA ACC CTT TCT GTG AAA GGC ACC-3' (SEQ ID NO:15)

5 Polymerase chain reaction amplification was conducted through the use of a Perkin-Elmer 9600 thermocycler for 30 cycles of 94°C, 55°C, and 72°C for 30 seconds each. The resulting amplification product, termed *vanHP* (*vanH* promoter) was then subcloned into the plasmid, pAMP1 (Gibco BRL, Rockville, MD), using the Cloneamp™ (Gibco BRL, Rockville, MD) cloning protocol.

10 The *vanA* gene was amplified using the following primer pair and subcloning the product into pAMP1 to create a plasmid designated pAMP1-*vanA* antisense:

5'-CUA CUA CUA CUA CTC GAG GCT TAT CAC CCC TTT AAC GC-3' (SEQ ID NO:16)

5'-CAU CAU CAU CAU GGA GAC AGC ATG AAT AG-3' (SEQ ID NO:17) ..

15 The polymerase chain reaction with these primers consisted of 30 cycles of 94° C, 55°C, and 72°C for 35 seconds each.

Enterococcal Electroporation

Transformation of the *Enterococcus faecalis* strains with pAM401, pAM401-*vanHP*, or pAM401-*vanHP-vanA* antisense was accomplished via electroporation with a Biorad Gene 20 Pulser™ (Friesenegger, et al., *FEMS Microbiol. Letter*, 1991;79:323-328) . In this procedure, 40 ul of electrocompetent enterococci were combined in a sterile 0.1 cm electroporation cuvette with 2 µl of purified plasmid DNA. The electroporation apparatus settings were 1.50 volts and 400 ohms. Under these conditions, resultant time constants are typically in the 9 millisecond range.

Vancomycin Susceptibility Assays: Agar and Broth Dilutions

25 Vancomycin susceptibilities were determined using the standard National Committee for Clinical Laboratory Standards (NCCLS) agar dilution protocol (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A4. Wayne, PA: NCCLS, 1997). In this assay, the test antibiotic, in this case, vancomycin, was incorporated into Mueller Hinton II agar medium (Becton Dickenson) at two-fold dilutions ranging from concentrations of 0 µg/ml up to 512 µg /ml. The agar was then poured into respective sterile plates. Bacterial strains were then inoculated onto the agar plates and incubated at 35°C overnight. The

-27-

minimum inhibitory concentration (MIC) was then determined by the lowest concentration of antibiotic that completely inhibited colony growth.

Gene Expression-RT-PCR

A single colony of A407 with the pAM401-*vanHP-vanA* antisense construct was grown in brain-heart infusion (BHI) liquid media with sub-inhibitory concentrations of vancomycin (1 µg/ml) and chloramphenicol (10 µg/ml). Bacterial RNA was prepared using the Qiagen RNeasy® protocol for the isolation of total RNA (Qiagen Inc. Valencia, CA) modified to incorporate a step of treatment with RNase free DNase applied directly on the QIAamp® column (both Qiagen Inc. Valencia, CA). Then a modified Titan™ One tube RT-PCR protocol (Roche molecular biochemicals, Indianapolis, IN) was followed. The samples were then reverse transcribed and amplified by one-step RT-PCR. Each reaction mix contained template RNA (5µg), enzyme (either Titan enzyme mix, reverse and forward PCR primers and buffer components recommended for optimal enzyme activity. The forward (5'-CUA CUA CUA CUA CTC GAG GCT TAT CAC CCC TTT AAC GC -3' -SEQ ID NO:16) and the reverse primer (5'-CGA ATA CCG CAA GCG ACA G-3' -SEQ ID NO:25) were designed to amplify a 1.1 kb bacterial RNA sequence. The RT reaction was performed at 45°C for 60 min, followed by PCR in a Perkin Elmer Model 9600 Thermal Cycler with the following thermal profile: Initial denaturation: 95°C for 3 min then 35 cycles of denaturation (93°C, 15 s), annealing (55°C, 30 s), elongation (68°C, 70 s) and a final extension step (72°C, 7 min). Amplification products were analyzed by gel electrophoresis.

Results

Changes in Vancomycin Phenotypic Susceptibility

The vancomycin susceptibility of a *vanA* *Enterococcus faecalis* strain, A407, was assessed after electroporation with either pAM401; pAM401-*vanHP*; or pAM401-*vanHP-vanA* antisense. While the vancomycin minimum inhibitory concentration (MIC) remained at 128 µg/ml in A407 containing the pAM401 shuttle vector alone, the introduction of pAM401 with the *vanH* promoter decreased the vancomycin MIC to 16 – 32 µg/ml. The vancomycin MIC was further decreased in response to the pAM401 containing both the *vanH* promoter and the *vanA* antisense, typically in the 8 µg/ml range.

VanH promoter effect on vancomycin resistance

The p*VanR* binding domain within the *vanH* promoter has previously been characterized and consists of an approximate 80 bp region that is considered to have the capacity to bind multiple p-*VanR* molecules (Holman, et al., *Biochemistry*, 1994, 33:4625-

-28-

31). Therefore, it was reasoned that the introduction of an exogenous *vanH* promoter cloned into a recombinant enterococcal shuttle vector could increase the vancomycin susceptibility of a target VanA enterococcal isolate through the binding and sequestration of p*VanR* from the native *vanH* promoter. As an initial test of this hypothesis, pAM401 enterococcal shuttle vectors with or without the *vanH* promoter were constructed and electroporated into a VanA strain of *E. faecalis* (A407). The successful transfer of the vectors by electroporation was confirmed through the purification of shuttle vector plasmids from the transformants followed by restriction digest analysis as well as by dideoxy-sequencing. To confirm that MIC changes in the transformants were not related to the loss of the VanA operon, the retention of the resistance determinant gene cluster was confirmed by the polymerase chain reaction (PCR) amplification of relevant genes.

Using both agar and broth dilution methods to determine antibiotic susceptibilities after shuttle vector electroporation, the vancomycin MIC of A407 enterococci transformed with the shuttle vector containing the *vanH* promoter (pAM401-*vanHP*) demonstrated a four-fold reduction in the MIC from 256 µg/mL to 64 µg/mL. In contrast and as expected, control A407 enterococci transformed with the pAM401 vector alone maintained the baseline (MIC of 256 µg/mL) resistance phenotype.

To further support that the vancomycin-resistance phenotypic changes seen with the transformation of pAM401-*vanHP* were due to a transcriptional activator binding decoy effect, the p*VanR* binding domain portion of the *vanH* promoter was amplified and cloned into pAM401 (pAM401-p*VanR*-BD+). As a control, a shuttle vector containing a mutant p*VanR* binding domain-deficient *vanH* promoter (pAM401-p*VanR*-BD-) was also constructed. Consistent with the phenotypic effects seen with the entire *vanH* promoter, the transfer of the p*VanR* binding domain (pAM401-p*VanR*-BD+) into A407 enterococci similarly resulted in a four-fold decrease in the vancomycin MIC to 64 µg/mL. As predicted, no vancomycin susceptibility change resulted from the introduction of the pAM401-p*VanR*-BD- vector.

Effects of vanH promoter-driven vanA antisense RNA expression

Recombinant pAM401 shuttle vectors were then created which contained a gene cassette consisting of the *vanH* promoter and downstream *vanA* antisense gene (pAM401-*vanHP*-*vanA* antisense), a configuration in which antisense expression would thus be upregulated in parallel that of the native VanA operon in the presence of vancomycin. A control vector that expressed *vanH* promoter-driven *vanA* sense transcripts was also cloned

-29-

(pAM401-*vanHP*-*vanA* sense) and was electroporated into respective A407 VanA *E. faecalis*. The expression of the *vanH* promoter-*vanA* coding and antisense messenger RNA were confirmed by reverse transcriptase PCR (RT-PCR). In A407 *E. faecalis* electroporated with pAM401-*vanHP*-*vanA* antisense, the vancomycin MIC was reduced to a susceptible range, from 256 µg/mL to 2 µg/mL. As predicted, the MIC of A407 transformed with pAM401-*vanHP*-*vanA* sense remained at the baseline level of 256 µg/mL.

Discussion

A gene cassette targeting a key antibiotic resistance determinant of the clinically relevant Gram-positive bacterium, *Enterococcus*, has been constructed and consists of the enterococcal *vanH*-promoter driving the expression of a *vanA* antisense gene introduced in an enterococcal shuttle vector. The target gene, *vanA*, is a highly conserved component of a gene cluster that confers high-level resistance to vancomycin, a pivotal antibiotic used to treat infections caused by *Enterococcus* resistant to beta-lactam antibiotics. The *vanH* promoter employed in this construct is the same inducible enterococcal promoter which drives expression of the *vanA* resistance determinant expression (Figure 3). In such an arrangement, where both the resistance and anti-resistance determinant expression are driven by the same inducible promoter, the enterococcal transcriptional factor, phosphorylated *VanR* (p*VanR*), which induces the *vanH* promoter (Arthur, et al., *J. Bacter.*, 1992, 174:2582-2591), is at the same time, sequestered from the native *vanH* promoter, but also allows for induction of the anti-*vanA* antisense in parallel with the expression of the *vanHAX*. In short, this gene cassette inhibits vancomycin resistance both by an inducible antisense mechanism as well as by functioning as a transcriptional factor binding decoy (Figure 4). Reflective of such a dual mechanism, recombinant shuttle vectors containing the *vanH* promoter or the p*VanR* binding domain effected a partial restoration of vancomycin susceptibility, while full restoration of vancomycin susceptibility resulted with the introduction of a vector containing both *vanH* promoter and *vanA* antisense gene. More specifically, the introduction of a shuttle vector containing the *vanH* promoter alone into a vancomycin-resistant, *vanA*-containing *Enterococcus faecalis* resulted in up to a 16-fold reduction of the minimum inhibitory concentration for vancomycin while a shuttle vector containing both *vanH* promoter and *vanA* antisense increased vancomycin susceptibility even further (approximately 32-fold).

Given the increasingly important role of drug-resistant Gram-positive bacteria such as vancomycin-resistant *Enterococcus* as a cause of significant human disease, combined with a

-30-

dearth of effective pharmacological therapeutic options for this pathogen, novel strategies as described above, have several potential applications for (1) the treatment primary infections (2) the eradication of vancomycin-resistant *Enterococcus* from areas which are frequently colonized (e.g. intensive care units, dialysis units, individual patient's bowel flora, the agricultural setting) and (3) as a laboratory tool for the study of antibiotic resistance gene function and pathogenesis.

Recombinant shuttle vectors which target other genes in the *vanA* operon such as *vanX*, as well as polycistronic vectors which contain genetic elements designed to interfere with multiple VanA operon functions (e.g. *vanA*, *vanH*, and *vanX*), can be constructed using routine experimentation and no more than ordinary skill in the art. Given that an operon analogous to that associated with the VanA phenotype also forms the genetic basis for class B (VanB) vancomycin resistance, analogous compositions against Class B (VanB), as well as other classes of vancomycin resistance operons and genes can be developed as described above. For example, a *vanX* antisense strategy analogous to the *vanA* antisense strategy was also tested, resulting in lowering vancomycin MICs to the 2 µg/ml range.

Such compositions optimally include gene delivery systems such as bacteriophage, highly efficient transconjugative plasmids, and peptide-nucleic acids.

Detailed Description of the Drawings

Figure 1. The VanA vancomycin resistance operon. *vanR* represents a response regulator which, after phosphorylation, activates the *vanH* promoter which results in activation of *vanH*, *vanA*, and *vanX* transcription; *vanS*, a signal sensor, is responsible for the inducibility of the operon by glycopeptide antibiotics;; the *vanH* gene product is a dehydrogenase that generates lactate from pyruvate; *vanA* codes for a ligase which preferentially synthesizes D-ala-D-lac; *vanX* codes for a dipeptidase which degrades the native D-ala-D-ala produced by the wildtype ligase; *vanY* is a carboxypeptidase which removes terminal alanines; *vanZ* is responsible for increased resistance to teicoplanin.

Figure 2. Maps of the shuttle vectors and relevant cloning sites. (A) The parent vector, pAM401. This vector is composed of both *Enterococcus faecalis* (shaded half on right) and *Escherichia coli* (bold portion on left) components. The *cat* region is the chloramphenicol acetyl-transferase gene. The *tet* region is the tetracycline resistance gene. (B) The *vanH* promoter insertion. (C) The *vanA* antisense insertion.

-31-

Figure 3. The proposed nucleic acid binding decoy mechanism by which the observed vancomycin minimum inhibitory concentrations are reduced with the introduction of the pAM401 shuttle vector with the *vanH* promoter alone.

Figure 4. A schematic of the proposed mechanism-of-action of the pAM401-*vanH* promoter-*vanA* antisense recombinant shuttle vector.

All terms used herein have their conventional meaning unless otherwise indicated.

All patents and other documents disclosed in this application are incorporated in their entirety herein by reference.

While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

What is claimed is followed by the Abstract and a Sequence Listing.

We claim:

-32-

Claims

1. A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising:
introducing into the organism at least one anti-sense vancomycin resistance molecule under conditions to inhibit expression of a vancomycin resistance gene.
2. The method of claim 1, wherein the vancomycin resistant organism is selected from the group consisting of the Gram-positive bacteria, *Enterococcus faecalis* and *Enterococcus faecium*, and other Gram-positive bacteria such as *Staphylococcus species*, and *Streptococcus species*, to which these organisms have the potential of transferring resistance determinants.
3. The method of claim 1, wherein the vancomycin resistant organism is a Gram-positive bacteria.
4. The method of claim 3, wherein the Gram-positive bacteria is an enterococcus.
5. The method of claim 1, wherein the vancomycin resistant organism is selected from the group consisting of a VanA resistant organism, a VanB resistant organism, a VanC resistant organism, and a VanD resistant organism.
6. The method of claim 1, wherein the vancomycin resistant organism is a vanA resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanA* anti-sense molecule, a *vanR* antisense molecule, a *vanS* anti-sense molecule, a *vanH* anti-sense molecule, a *vanX* anti-sense molecule, a *vanY* anti-sense molecule and a *vanZ* anti-sense molecule.
7. The method of claim 1, wherein the vancomycin resistant organism is a VanB resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanRB* anti-sense molecule, a *vanSB* anti-sense molecule, a *vanYB* anti-sense molecule, a *vanW* anti-sense molecule, a *vanHB* anti-sense molecule, and a *vanXB* anti-sense molecule.

-33-

8. The method of claim 1, wherein the anti-sense vancomycin resistant organism is a VanC resistant organism.

9. The method of claim 1, wherein the vancomycin resistant organism is a VanD resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanD* anti-sense molecule, a *vanRD* anti-sense molecule, a *vanSD* anti-sense molecule, a *vanYD* anti-sense molecule, a *vanHD* anti-sense molecule, and a *vanXD* anti-sense molecule.

10. The method of claim 1, wherein the anti-sense vancomycin resistance molecule is a *vanA* antisense molecule selected from the group consisting of:

an antisense molecule that hybridizes to the complete *vanA* gene sequence; and
an antisense molecule that hybridizes to a conserved region of the *vanA* gene sequence.

11. The method of claim 10, wherein the *vanA* antisense molecule hybridizes to a conserved region of the *vanA* gene including from 10 to 30 nucleotides.

12. The method of claim 11, wherein the *vanA* gene encodes an enzyme and the *vanA* antisense molecule hybridizes to a region of the *vanA* gene which encodes an active site of the ligase.

13. The method of claim 1, wherein introducing the anti-sense vancomycin resistance molecule comprises contacting the vancomycin resistant organism with at least one vector comprising one or more "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes.

14. The method of claim 13, wherein the vector is selected from the group consisting of: an enterococcal shuttle vector, an enterococcal or any other species or strain of bacteriophage; the nucleic acid portion of a peptide nucleic acid molecule; an enterococcal conjugative transposon or a pheromone-responsive plasmid.

-34-

15. The method of claim 14, wherein the vector is an enterococcal shuttle vector.
16. The method of claim 13, wherein the vector contains a single copy of a *vanA* antisense molecule.
17. The method of claim 13, wherein the vector contains multiple copies of a *vanA* antisense molecule.
18. The method of claims 16 or 17, wherein the vector comprises a *VanR*-responsive promoter operatively coupled to the *vanA* antisense molecule.
19. The method of claim 1, wherein the anti-sense vancomycin resistance molecule is a *vanX* antisense molecule selected from the group consisting of:
 - an antisense molecule that hybridizes to the complete *vanX* gene sequence; and
 - an antisense molecule that hybridizes to a conserved region of the *vanX* gene sequence.
20. A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising:
 - enhancing expression of a *vanH* promoter in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism.
21. The method of claim 20, wherein the *vanH* promoter is operatively coupled to an antisense vancomycin resistance molecule.
22. The method of claims 20 or 21, wherein the *vanH* promoter is contained on an enterococcus vector and enhancing expression comprises introducing into the organism an amount of the vector to express an amount of the *vanH* promoter sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism.
23. The method of claim 20, further comprising co-administering into the organism an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter.

-35-

24. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NOs:1-13.
25. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NOs:5-13.
26. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs:5-10.
27. A vector comprising an isolated nucleic acid molecule of any of claims 24, 25 or 26.
28. The vector of claim 27, further comprising a *vanH* promoter operatively coupled to the isolated nucleic acid molecule.
29. An isolated vancomycin resistant organism comprising a vector of claim 27 or 28.

Figure 1.



**SUBSTITUTE SHEET (RULE 26)**

Figure 2.



SUBSTITUTE SHEET (RULE 26)





Figure 3.

SUBSTITUTE SHEET (RULE 26)



-1-

SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center, Inc.
 Inouye, Roger T.
 Torres-Viera, Carlos
 Moellering, Robert
 Gold, Howard
 Eliopoulos, George M.

<120> METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT ENTEROCOCCUS

<130> B0662/7036WO/ERP/KA

<150> U.S. 60/149,313
<151> 1999-08-17

<160> 39

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 10851
<212> DNA
<213> Enterococcus faecium

<400> 1

gggttagcgt cagg	aaatg	cggatttaca	acgctaagcc	tattttcctg	acgaatccct	60
cgaaaaac	aacgttaaga	aagttttagt	ggtcttaaag	aatattaatga	gactacttcc	120
tctgagttaa	aatggtatttc	tcctagtaaa	ttaatataatgtt	cccaacctaa	gggcgacata	180
tgggtgttaca	aatcttcatt	aaagctacct	gtccgttttt	tatattcaac	tgctgttgtt	240
agggtggagag	tattccaaat	acttatacgca	ttgataatta	tgtttaaagc	actggctctt	300
tgcattgtat	gctgtatggt	gctttctcta	agctcacett	gttttccgaa	aaaaatagct	360
cttgcataatc	cattcatggc	ttctccttta	ttcaatcetc	tttgtatttt	tcttccttaat	420
gattccatccg	atataataatt	caaaaataaaag	atcgtttttt	ctatccggcc	catctcacgt	480
aaggctgttag	ctaagctgtt	ttgtcttgaa	taggaaccta	gctccccat	aataagggt	540
gctgaaactg	tccctccct	tatagaatga	gctaatacgca	aaacatccctc	ataatttct	600
ttaatgacct	ttgtatTTT	ttgtccacgt	aaaatggctt	ctagttttgg	ataactcactt	660
gctttatcta	tcgtaaataa	ttttgagtcc	gataaaatccc	ttattcttgg	ggcaaattta	720
aatccataata	aatgagtcag	tccgaatatt	tggtcagtgt	aaccggcagt	gtctgtataa	780
tgttccctcta	tgttttagatc	cgtctcatga	tgttaacaaac	catccaaaac	atgaatcgca	840
tctcttgaat	tagtatgaat	aatctttgtg	tagtaagaag	agaattgtac	acttggtaat	900
cggtagatgg	tggctcctt	tccagttcca	taatgtggat	ttgcacatcgc	atgttagtgat	960
gaaacaccta	gctgcattct	cataccatct	gacgaagatg	ttgtaccgtc	gccccaaatag	1020
aaaggcaatt	gtaatTTT	atgaaaagttt	actaatatgg	cttgggcttt	attcatggca	1080
tcttcataca	tgcgccattg	agatacattg	gctagttgt	tatatgtaaag	tccgggtgt	1140
gcttcggcca	tcttgctcaa	gccaatattc	attcccatcc	ctaaaagggc	agccatgata	1200
atgattgttt	cttccttatac	tggTTTcga	ttattggaaag	catgagtgaa	ttgctcatga	1260
aatccctgtta	tatgggccac	atccatgagt	aaatcagttt	attttattct	tggtagcattc	1320
tgataaaaggc	ttgcactaaa	ttttttgtct	tcttcgtgaa	catcttttc	taagcgtgca	1380
agtgatagct	ttcccttttc	aagagaaaacc	ccatctaact	tattggaaatt	ggcagctaacc	1440
cactttaacc	tttcattaaa	gctgctggtt	ctctccgtt	tataatcttc	gaatgataaaa	1500
ctaactgtata	atctcgtatt	ccccctcgat	tgattccatg	tatctccgaa	aaacaaatata	1560
tcctcaaaat	ccctatattg	tctgctgcca	acaatggaaa	catctcctgc	ccgaacatgc	1620
tcctcggat	ctgtaaaaac	agccatttca	tagtaatgac	gattaattgt	tgtaccatca	1680
tcctcgtata	aatgtctttt	ccatcgTTT	gaaataaaaat	ccacagggtga	gtcatcaggc	1740
acttttcgct	ttccagattc	gttcattcct	cggataatct	caacagcttg	taaaagtggc	1800

-2-

tcatttgcct	ttgtagaatg	aaattccaat	actcttaata	gcgttggcgt	atattttctt	1860
agtgaataaaa	accgttttg	cagtaagtct	aaataatcat	agtcggcagg	acgtgcaagt	1920
tcctgagcct	cttctactga	agagacaaag	gtattccatt	caataaccga	ttctaaaacc	1980
ttaaaaacgt	ctaattttc	ctctcttgct	ttaattaatg	cttgcgcgat	ttcgtaaag	2040
tgtataactt	tctcatttag	cttttaccg	tttgcgttct	ggatttcctc	ttgagcctta	2100
cgacctttg	ataacaaact	aagtattgc	ctatcatgaa	ttcaaacgc	tttatccgtt	2160
agctcctgag	taagttgtaa	taaatagatg	gttaatatcg	aataacgttt	attttcttga	2220
aagtacacgga	atgcatacgg	ctcgatctt	gaggcttaagc	gagacagctg	caacaggcgg	2280
ttacggcga	aatgactaat	ttgcactgtt	tctaaatcca	ttcctcgat	gtattcgagt	2340
cgttctatta	tttttagaaa	agtttcgggt	gaaggatgac	ccggtggttc	ttttaaccaa	2400
cccaatatcg	ttttattgga	ttcgatgga	tgctgcgagg	taataatccc	ttcaagctt	2460
tcttttgc	catttgcgtt	agatttacta	accgttataa	atagcttctt	ttcagccatt	2520
gcccttgcct	ccccacccat	tcttcaggat	gtagtgtatag	caggcagtat	aattttgtt	2580
tttcttagaa	aatctatgca	ttcatgcagt	agatgaatgg	catcaccatt	ttccaaagct	2640
aattgtgaa	ggtacttaaa	tgtcatcga	tattcactca	gggtaaaagt	tacaaagtcg	2700
tattcaettc	gaatttcttt	caaataatgatcc	caaagtgttat	tttccctttg	aggataataga	2760
tcaagcgagg	atggactaac	accatctgt	ttcgatataat	attgtatgac	cgaatctggg	2820
atgttttga	tatgagtgtt	tggccaaccg	ggataccgaa	gaacagctaa	ttgaacagca	2880
aaectaaac	ggttttcttc	cctccttcgc	tttataacta	tttctaaatc	ccgtttggaa	2940
aaagtgaagt	aggccccag	tatccattca	tcttcaggga	tttgcataaaa	agcctgtc	3000
tgttccgggt	taagcaattc	tctacccctc	geaattttca	ttcagttatca	ttccattttt	3060
gtattttcaa	tttatttagtt	caatttatata	tcaatagatgt	gtacttatt	gataaaaaatg	3120
tagtagactg	ataaaatcat	agttaaagagc	gtctcataaag	acttgtctca	aaaatgaggt	3180
gatattttgc	ggaaaatcgg	ttatattcgt	gtcagttcga	ctaaccagaa	tccttcaaga	3240
caatttcagc	agttgaacga	gatcggaaatg	gatatttatat	atgaagagaa	agtttcaggaa	3300
gcaacaaagg	atcgcgagca	acttcaaaaa	gtgttagacg	atttacagga	agatgacatc	3360
atttatgtta	cagacttaac	tcgaatcact	cgttagtacac	aagatcttatt	tgaattaaatc	3420
gataacatac	gagataaaaa	ggcaaggat	aaatcactaa	aagatacatg	gttgattta	3480
tcagaagata	atccatacag	ccaaattctt	attactgtaa	tggctgggt	taaccaatata	3540
gagcgagatc	ttattcggat	gagacaacgt	gaagggattt	aattggctaa	aaaagaagga	3600
aagtttaaag	gtcgattaaa	gaagttatcat	aaaaatcacc	caggaatgaa	ttatgcggta	3660
aagctatata	aagaaggaaa	tatgactgtt	aatcaaattt	gtgaatttac	taatgtatct	3720
agggcttcat	tatacaggaa	attatcagaa	gtgaaaaattt	agccattctg	tattccgcata	3780
atgggcaata	tttttaaaga	agaaaaaggaa	actataaaaat	attaacagcc	tccttagcgt	3840
gccggaaaagc	cctttgataa	aaaaagaatc	atcatcttaa	gaaattctt	gtcattttatt	3900
atgtaaatgc	ttataaattc	ggccctataa	tctgataaaat	tattaaggc	aaacttatgt	3960
gaaagggtga	taactatgag	cgataaaaata	cttattgtgg	atgatgaaca	tgaaaattgcc	4020
gatttgggt	aattataactt	aaaaaaacgg	aattatacgg	tttcaaaata	ctataccggcc	4080
aaagaagcat	tggatgtat	agacaagtct	gagattgacc	ttgccatatt	ggacatcatg	4140
cttccggca	caagcggcct	tactatctgt	aaaaaaaataa	gggacaagca	cacctatcg	4200
attatcatgc	tgaccgggaa	agatacagag	gtagataaaa	ttacagggtt	aacaatcg	4260
gcggatgatt	atataacgaa	gccctttcgc	ccactggagt	taattgcgt	gtttaaggcc	4320
cagttgcgcc	gataaaaaaa	attcagtgga	gtttaaggagc	agaacaaaaa	tggtatcg	4380
cactccggcc	ttgtcattaa	tgttaacacc	catgagtgtt	atctgaacga	gaagcagtta	4440
ccctttaactc	ccaccgagtt	ttcaataactg	cgaatcctct	gtgaaaacaa	ggggaaatgt	4500
gttagctccg	agctgctatt	tcatgagata	tggggcgcac	aatatttcag	caagagcac	4560
aacaccatca	ccgtcataat	ccggcatttg	cgcgaaaaaaa	tgaacgacac	cattgataat	4620
ccgaaatata	aaaaaaacgg	atgggggtt	ggttataaaa	ttgaaaata	aaaaaaacga	4680
ctattccaaa	ctagaacgaa	aactttacat	gtatatcggt	gcaattgtt	ttgttagcaat	4740
tgtattcgt	ttgtatattc	gttcaatgat	ccgaggggaaa	cttggggatt	ggatcttaag	4800
tatTTggaa	aacaaatatg	actttaatca	cctggacgc	atgaaattat	atcaatattc	4860
catacggAAC	aatatagata	tcttttattt	tgtggcgtt	gtcatttagta	ttcttattt	4920
atgtcgcgtc	atgcttcaa	aattcgaaa	atactttgac	gagataaata	ccggcattga	4980
tgtacttatt	cagaacgaag	ataaaacaaat	tgagctttct	gcggaaatgg	atgttatgg	5040
acaaaagctc	aacacattaa	aacggactct	ggaaaagcga	gagcaggatg	caaagctggc	5100
cgaacaaaga	aaaaatgacg	ttgttatgtt	cttggcgcac	gatattaaaa	cgcccccttac	5160
atccattattc	ggttatttga	gcctgcgtt	cgaggcttca	gacatgcccgg	tagatcaaaa	5220

-3-

ggcaaagtat	gtgcataatca	cgttggacaa	agcgtatcga	ctcgaacacg	taatcgacga	5280
gtttttgag	attacacggt	ataacctaca	aacgataacg	ctaacaaaaaa	cgcacataga	5340
cctatactat	atgctggtc	agatgaccga	tgaattttat	cctcagctt	ccgcacatgg	5400
aaaacaggcg	gttattcacg	cccccgagga	tctgaccctg	tccggcgacc	ctgataaact	5460
cgcgagagtc	tttaacaaca	tttgaaaaaa	cgccgctgca	tacagtgggg	ataacagcat	5520
cattgacatt	acccggggcc	tctccgggga	tgtggtgtca	atcgaattca	agaacactgg	5580
aagcatccca	aaagataacg	tagctgccat	atttgaaaaag	ttctataggc	tggacaatgc	5640
tcgttcttc	gatacgggtg	gcgcgggact	tggattggcg	attgcaaaag	aaattattgt	5700
tcagcatgga	gggcagattt	acgcggaaag	caatgataac	tatacgacgt	ttagggtaga	5760
gcttccagcg	atgccagact	tggttgataa	aaggaggtcc	taagagatgt	atataatttt	5820
tttagaaaaat	ctcaagggtt	tcttacttt	ttcttaggaa	attaacaatt	taatattaag	5880
aaacggctcg	ttcttacacg	gtagacttaa	taccgttaaa	acgagccgtt	ttcgttcttc	5940
agagaaagat	ttgacaagat	taccattggc	atccccgtt	tatttggtgc	ctttcacaga	6000
aagggttggt	cttaattatg	aataacatcg	gcattactgt	ttatggatgt	gagcaggatg	6060
aggcagatgc	attccatgtc	cttgcgcctc	gctttggcgt	tatggcaacg	ataattaacg	6120
ccaacgtgtc	ggaatccaac	gccaaatccg	cgcccttcaa	tcaatgtatc	agtgtggac	6180
ataaatcaga	gatttccgc	tctatttttc	ttgcgetgaa	gagagccgt	gtgaaatata	6240
tttctacccg	aagcatcgcc	tgcaatcata	tagatacaac	tgctgctaag	agaatggca	6300
tcactgtcga	caatgtggcg	tactgcgcgg	atagcgttgc	cgattatact	atgatgctaa	6360
ttcttatggc	agtacgcaac	gtaaaatcga	ttgtgcgtc	tgtggaaaaaa	catgattca	6420
ggttggacag	cgaccgtggc	aaggtaacta	gcgcacatgac	agttgggtgt	gtgggaacgg	6480
gccagatagg	caaagcggtt	attgagcgcc	tgcgaggatt	tggatgtaaa	gtgttggctt	6540
atagtgcag	ccgaagtata	gaggtaaact	atgtaccgtt	tgatgagttg	ctgcaaaata	6600
gcgatatcgt	tacgcttcat	gtgcccgtca	atacggatac	gcactatatt	atcagccacg	6660
aacaaataca	gagaatgaag	caaggagcat	ttcttataaa	tactgggcgc	ggtccacttg	6720
tagataccta	tgagttggtt	aaagcattag	aaaacgggaa	actggggcggt	gccgcattgg	6780
atgtatttgg	aggagaggaa	gagttttct	actctgtatt	cacccaaaaaa	ccaattgata	6840
atcaattttt	acttaaaac	caaagaatgc	ctaacgtgt	aatcacacccg	catacggcct	6900
attataccga	gcaagcgttg	cgtgataaccg	ttgaaaaaaac	cattaaaaac	tgtttggatt	6960
ttgaaaggag	acaggagcat	gaatagaata	aaagttgcaa	tactgtttgg	gggttgcgtca	7020
gaggagcatg	acgtatcggt	aaaatctgca	atagagatag	ccgctaacat	taataaagaa	7080
aaatacggac	cgttatacat	tggaaattacg	aaatctgggt	tatggaaaaat	gtgcgaaaaaa	7140
ccttgcgcgg	aatggggaaaa	cgacaattgc	tattcagctg	tactctcgcc	ggataaaaaaa	7200
atgcacggat	tacttggtaa	aaagaaccat	gaatatgaaa	tcaaccatgt	tgatgtagca	7260
ttttcagctt	tgcatggcaa	gtcagggtgaa	gatggatcca	tacaagggtct	gtttgaattg	7320
tccgttatcc	cttttgtagg	ctgcgatatt	caaagctcag	caatttgtat	ggacaaatcg	7380
ttgacataca	tcgttgcgaa	aaatgtctgg	atagctactc	ccgccttttgc	ggttattaat	7440
aaagatgata	ggccgggtggc	agctacgttt	acctatcctg	tttttggtaa	gccggcgcgt	7500
tcagctcat	ccttcgggt	gaaaaaaagtc	aatagcgcgg	acgaatttgg	ctacgcaatt	7560
gaatccgcaa	gacaatatga	cagcaaaatc	ttaattgagc	aggctgtttc	gggctgtgag	7620
gtcggtgtg	cggtatttgg	aaacagtgc	gcgttagtt	ttggcggaggt	ggaccaaata	7680
aggctgcagt	acggaatctt	tcgtattcat	caggaagtcg	agccggaaaaaa	aggctctgaa	7740
aacgcagttt	taaccgttcc	cgcagacett	tcagcagagg	agcgaggacg	gatacaggaa	7800
acggcaaaaa	aaatatataa	agcgctcgcc	tgtagaggac	tagccctgt	ggatatgttt	7860
ttacaagata	acggccgcat	tgtactgaac	gaagtcaata	ctctgcccgg	tttcacgtca	7920
tacagtcgtt	atccccgtat	gatggccgt	gcaggtattt	cacttcccg	actgatttgc	7980
cgcttgcgt	tattagcgtt	aaaggggtga	taagcatgga	aataggattt	acttttttag	8040
atgaaatagt	acacgggtt	cgttgggacg	ctaaatatgc	cacttgggt	aatttcacccg	8100
gaaaaccgg	tgacggttat	gaagtaaatac	gcattgtagg	gacatacgg	ttggctgaat	8160
cgctttgaa	ggcaaaaagaa	ctggctgcta	cccaagggtt	cgatttgctt	ctatggacg	8220
gttaccgtcc	taagcgtgt	gtaaactgtt	ttatgcaatg	ggctgcacag	ccggaaaaata	8280
acctgacaaa	ggaaagttat	tatccaata	ttgaccgaac	tgagatgatt	tcaaaaaggat	8340
acgtggcttc	aaaatcaac	catagccgc	gcagtgcct	tgatcttacg	ctttatcgat	8400
tagacacggg	tgagttgtt	ccaatgggg	gcccatttga	ttttatggat	gaacgctctc	8460
atcatgcggc	aaatggaata	tcatgcaatg	aagcgaaaaaa	tcgcagacgt	ttgcgttcca	8520
tcatggaaaa	cagtgggtt	gaagcatata	gcctcgaatg	gtggcactat	gtattaagag	8580
acgaaccata	ccccaaatagc	tattttgatt	tcccgtaaa	ataaaactttt	aaccgttgca	8640

-4-

cggacaaaact atataagcta actcttcgg cagggaaaccc gacgtatgta actggttctt	8700
agggaaattta tatatagttag atagtattga agatgttaagg cagagcgata ttgcggtcat	8760
tatctgcgtg cgctgcgcga agatagcctg ataataagac tgatgcata gaggggttgt	8820
atttcacacc gcccattgtc aacaggcagt tcagcctcgtaaaattcagc atgggtatca	8880
cttatgaaaa ttcatctaca ttggtgataa tagtaaatcc agtagggcga aataattgac	8940
tgttaattac ggggcaaaac ggcacaatct caaacagagat tggccgtt aaggggaaaga	9000
ttctagaaat atttcataact tccaaactata tagttaagga ggagactgaa aatgaagaag	9060
ttgtttttt tattgttatt gttattctta atatacttag gttatgacta cgttaatgaa	9120
gcactgtttt ctcaggaaaa agtcaattt caaaaattatg atcaaaatcc caaagaacat	9180
ttagaaaata gtgggacttc tgaaaatacc caagagaaaa caattacaga agaacaggtt	9240
tatcaaggaa atctgctatt aatcaatagt aaatatcctg ttgcccaaga aagtgtgaag	9300
tcagatatcg tgaatttattc taaacatgac gaattaataa atgatacgg gttgcttgat	9360
agtaatattt atatgtcaaa agaaatagca caaaaatttt cagagatggt caatgatgct	9420
gtaaagggtg gcgttagtca ttttattt aatagtggct atcgagactt tgatgagcaa	9480
agtgtgtttt accaagaaat ggggctgag tatgccttac cagcaggta tagtgagcat	9540
aattcagggtt tatcactaga tgttaggatca agcttgcga aaatggaaacg agccccctgaa	9600
ggaaagtggta tagaagaaaa tgcttgaaa tacgggttca tttacgttacca tccagaggac	9660
aaaacagagt taacaggaat tcaatatgaa ccatggcata ttgcctatgt tggtttacca	9720
catagtgcga ttatgaaaaga aaagaatttc gttctcgagg aatatatggta ttacctaaaa	9780
gaagaaaaaa ccattttctgt tagtgtaaat ggggaaaaat atgagatctt ttattatcct	9840
gttactaaaa ataccaccat tcatgtgccc actaatttt gttatgagat atcaggaaac	9900
aatatagacg gtgttaattgt gacagtgtttt cccggatcaa cacatactaa ttcaaggagg	9960
taaggatggc ggaatgaaaac caacgaaattt aatgaacagc attattgtac tagcacttt	10020
ggggtaacgt tagctttta attaaaacc cacgttaact aggacattgc tatactaatg	10080
atacaactta aacaaaagaa ttagaggaaa ttatattggg aaaaatatta tctagaggat	10140
tgctagctttt atatttagt acactaatct ggttagtgtt attcaaattta caatacaata	10200
ttttatcagt atttaatttat catcaaagaa gtcttaactt gactccattt actgctactg	10260
ggaatttcag agagatgata gataatgtta taatctttat tccatttggc ttgctttga	10320
atgtcaattt taaagaaaatc ggatttttac ctaagtttgc tttgtactg gtttaagtc	10380
ttacttttga aataattcaa ttatcttgc ctattggagc gacagacata acagatgtaa	10440
ttacaaatac tggggaggc ttcttggac tggaaattata tgggtaagc aataagcata	10500
tgaatcaaaa aaaatttagac agagtttata tttttgttagg tatacttttgc tctgtattat	10560
tgctcgaaaa ccgtaccat taaagaataa attacgtgtt agatgtctaa atcaagaata	10620
ctgatcttc atacacataa agatattgaa tgaattggat tagatggaaa acgggatgtg	10680
ggggaaactcg cccgttaggtg tgaagtgagg ggaaaaccgg tgataaaagta aaaagcttac	10740
ctaacactat agtaacaaaag aaagcccaat tatcaatttt agtgcgtgagg aattggtctc	10800
tttaataaaat ttcccttaacg ttgttaatcc gcattttcct gacggtagcc c	10851

<210> 2
 <211> 7160
 <212> DNA
 <213> Enterococcus faecalis

<400> 2	
tttaaacggat atatttgcga agaactgtgg aaacggctta tctctgtaaa atggggcatt	60
acagggcggtt gggtaaaaaa gctctgcgtt ggacgattaa aatccgaaaa gaaatcgctt	120
tgaaactaca gggaaactac agactgttat gttatcttct taaatgggg gatttttatg	180
tcgatacgaa ttctacttgtt cgaggatgtt gatcatatct gcaatacagt aagggcggtt	240
ttggctgaag caagatgtt ggtggatgcc tgcacagatg gaaacgaagc acacaccaag	300
ttctatgaaa acacctatca actgggtattt ctgtatattt tgctggccgg tatgaatggg	360
catgaacttc tacgtgaatt tggggcgcaaa aatgataccccc ccattctgtat gatgacagcc	420
ctgtcggtt acgaaaacca aatccggggcg tttgtatgtt aggcagacga ctatgttacaa	480
aagccattca agatgcggat ttactaaag cgggtggaaag ccctgttacg ggcgcggcgt	540
gcgcgtggcaaa aggaatttcg tggggcagg ctgacacttc tgccggagga ttttagggta	600
ctttgtacgt gtacggagct gccctgtaca cgaaaagaat ttgaaatctt tttgtctgt	660

-5-

gtgcagaaca aaggcagaac cttAACCCat gaaATCATTt tGTCcccGat atGGGGatAT	720
gactttgacg gtGATGGCAG cacAGTCCAC actCATATCA aaaATCTGCG gGCAGAGCTG	780
ccggaaaata tcATCAAAC catCCGCGGT gtaggTTacc GATGGAGGA ATCATTATAA	840
tggAAAAGAAA agggatttc attaAGGTTT ttCCCTATAc GATCATTGTC CTGTTACTGC	900
ttgtcggtgt aacGGCAACA ctGTTGcac AGCAATTGt GTCTTATTC AGAGCGATGG	960
aagcacagca aacAGTAaaa tcCTATCAGC cATTGGTGGa ACTGATTcAG aATAGCGATA	1020
ggcttgatAT gcaAGAGGTG gcAGGGCTGT ttCACTACAA TAACCAATCC tttGAGTTT	1080
atATTGAAGA tAAAGAGGGA AGCtACTCT ATGCCACACC GAATGCCGAT ACATCAAATA	1140
gtgttagGCC cgACTTTCTT tatGTGGTAC ATAGAGATGA TAATATTGc ATTGTTGTC	1200
aaAGCAAGGC agGTGTGGGA ttGCTTATC aAGGGCTGAC aATTcGGGGa ATTGTTATGA	1260
ttgcgataAT ggttGATTc AGCCTTTAT GCGCGTATAT CTTGCGCGG cAAATGACAA	1320
cGCCGATCAA AGCCTTAGCG gACAGTGCgA ATAAAATGGC AAACCTGAAA GAAGTACCGC	1380
cGCCGCTGGA gCGAAAGGAT gagCTTGGCG cACTGGCTCA CGACATGcat TCCATGTATA	1440
tcaggcgtGAA agAAACCCATC GCAAGGCTGG aggATGAAAT CGCAAGGGAA CATGAGTTGG	1500
aggAAACACa CGCATATTC tttGGGGcAG CCTCTCATGA GTTAAAAACG CCCATCGCGG	1560
ctgtAAAGCtG tCTGTTGGAG gGAATGCTTG AAAATATCGG TGACTACAAA GACCATTCTA	1620
agtATCTGCG cGAATGcAT AAAATGATGG ACAGGcAGGG CAAACACCt TCCGAAATAC	1680
tggagcTTGT cAGCCTGAAC GATGGGAGAA tCGTACCCAT AGCCGAACCG CTGGACATAG	1740
ggcgcacGGT tgCCGAGGTG ctACCCGATT ttCAAAACCTT GGCAGAGGGCA aACAACCCAGC	1800
ggTTcGTcAc agATATTCA GCGGACAAA ttGTCCTGTC CGATCCGAAG CTGATCCAAA	1860
aggcGCTATC caATGTcATA ttGAATGCGG ttCAGAAACAC GCCCCAGGGa GGTGAGGTAC	1920
ggATATGGAG tgAGCCTGGG gCTGAAAAAT ACCGTCTTc CGTTTGAAC ATGGCGTTc	1980
acATGTATGA tactGcACTT tCAAAGCTGT tCATCCCATt CTATCGCATT GATCAGGCc	2040
gaAGCAGAAA aAGTGGGCGA AGCGGTTGG ggCTTGCCAT CGTACAAAAA ACGCTGGATG	2100
ccATGAGCCT cCAATATGCG CTGGAAAACA CCTCAGATGG CGTTTGTTC TGGCTGGATT	2160
taccGCCcAC atCAACACTA tAAATATTa AAACtAAAt GATTTGACC GACAGGTATA	2220
accCTGCCGG tCTTTTGTt tttCGCGCT acAGGAAAC tacAGATTGA CtACAGGGAA	2280
agtACAGATA CGCTTGCCAT AtAAACAATC GTACCAGCCA CAAATCGTAG ttttATGcA	2340
aaggAGGcAT tCAATCAAAT GGAAAAAAAGC AACTATCATT CAAATGTGAA tCATCACAAA	2400
cggcatATGA aACAATCTGG GGAAAAAACGG GCTTTCTAT GGGCGTTCAT TATCTGTTc	2460
acAGTCTGcA CGCTGTTTT GGGGTGGAGA ttGGTTTCCG tATTGGAGGC AACACAGCTA	2520
ccgCCcATCC CTGcAACTCA tacAGGcAGC GGGACTGGT TAGCGGAGAA TCCAGAGGGa	2580
aACACTCTG CCACCGCCAA agAACAGGGa GATGAACAGG AATGGAGCCT GATTTAGTG	2640
aACAGGcAGA ACCCCATCCC CGCCcAGTAC GATGTGGAAc TTGAGCAGCT GTCACAAATGGT	2700
gAGCggATAG acATTcGGAT ttCTCCtAC tCCcAGGATT tGTTGATGC CGCAAGAGCT	2760
gATGGAGTTT accCGATTGt CGCATCCGGA tACCGGACAA CAGAAAAACa GCAAGAAATC	2820
atGGATGAAA aAGTCGCCGA ATACAAGGCG AAAGGCTACA CCTCTGcACA GGCTAAAGCG	2880
gaAGCAGAAA CTTGGTGGC CGTCCGGGA ACAAGCGAGC ATCAGCTGG tCTTGTGTG	2940
gATATCAATG CGGATGGAAT tCATTCACC GGCACACGGG TTACAGATG GCTGGATGAA	3000
aACAGCTATC GCTTTGGTTT tATTGCGCtC tACCCGCCAG ACAAGACAGA GATAACCGGT	3060
gtGAGCAACG AGCCGTGGCA ttACCGATAT GTCGGCATCG AAGCTGCCAC AAAGATAATC	3120
cACCAAGGGC tttGCTTGA gGAATATTa AACACAGAAA AATGAGAAAAA GGATAATG	3180
ctATGAACAG AAAAGATTG ACACAGCGCT tCCCGTTCT GCTTCAATG AGACAAGCGC	3240
AGAGAAAAT ATGCTTTAT GCGGGAAATGA GATTGACGG CTGTTGCTAT GCACAGACGA	3300
taggAGAAA AACGCTTCCC tATTGCTCT ttGAAACGGA ttGTGCGTTA tACAACCCACA	3360
atACCGGATT tgACATGATA tACCAAGAAA ACAAGGTtT CAACTAAAG CTGGCGGCAA	3420
AGACCTAAA CGGCCTATTG AtAAAACCGG GGGAAACCTT ttCTTTCTGG CGGCTGGTAC	3480
GCCATGCGGA CAAAGATAcc CCCTATAAAAG ACGGCCTAC GGTGGCCAAT GGTAAGCTCA	3540
CCACCATGTC GGGCGGCGGT ATGTGCCAGA TGAGCAATT ACTATTtGG GTGTTCTGC	3600
ATACGCCATT GACAATTATC CAGCGCAGCG GTCACGTAGT AAAGGAGTT CCAGAGCCAA	3660
ACAGTGAcGA GATCAAAGGG GTGGATGCAA CCACTCAGA GGGCTGGATT GATTTAAAAG	3720
TGCGAAACGA TACCGACTGC ACCTACAAA ATGGGTGAC CCTAGATGAT GAGAAAATCA	3780
TcGGTcAGGT GttcGCCGAC AAACAGCCTC AAGCATTATA CAAAATTGCA AACGGCAGTA	3840
ttcAGTATGT CCgtGAAAGt GGCAGGGATTt ATGAATATGC CAAGGTTGAA CGGATGcAAG	3900
ttGcCTTAgG tAccGGGGAA AtAAATAGATT GCAAGCTGT ttATACAAAC AAATGcAAA	3960
tctGCTATCC CCTCCCGGAA AGTGTGGATA ttCAGGAGGC GAAACCAATGA GAAAAGTAT	4020
gggcattACT GtttttGGAT GCGAGCAGGA tGAGGCAAAT GCTTCCGCA CTTATCACC	4080

-6-

agattttcat attatcccta cgctgatcag	tgatgcata tcggcagaca acgcaaaatt	4140
ggccgctggc aatcaatgca ttagcgtagg	ccataagtc gaggttccg aggcgacaat	4200
tcttgcgctg agaaaggctcg gggtaaaaata	catttctacc cgacgcatacg gctgaatca	4260
cattgatacg actgccccc agagaatggg	gatctcggtt ggcacagttt cgtattcgcc	4320
ggacagcggtt gcggattatg ctttgcgtct	gatgcgtatg gccatacggg gtgcaaagtc	4380
caccatacac gccgtggcgc aacaaaattt	cagactggat tggccggg ggaaagagct	4440
gcgggatatg actgtgggag ttattggAAC	cggccatata gggcaagcgg tcgtcaaaag	4500
gctgcgggga ttggatgcc gtgtgctagc	ctatgataac agccgaaaaa ttgaggcaga	4560
ttatgtccag cttgatgagc ttctaaaaaa	cagcgatatt gttacgctcc atgtccgct	4620
ttgtcggtat acccgccatc tgatcgccA	gagcgaatc ggagagatga agcaaggcgc	4680
attttaatc aacactggc gcggggcgct	tgtcgatacc gggtcgtgg tggaggcact	4740
gggaagcgg aagctggcg gtgcggcact	ggatgtgtt gaggcggagg atcagtttgt	4800
ttataccgac tgctcgacaa aagtgcgtGA	ccatccccttt ttgtcgacgc tcctaaggat	4860
gccaaatgtg atcatcacac cccatacggc	gtactacacc gagcgtgtgc tgcgagatac	4920
cacagaaaaa acaatcgaga attgtctAA	ctttgaaaagg agttacagc atgaataaaa	4980
taaaagtgcg aattatctc ggcggttgc	cggaggaaca tgatgtgtcg gtaaaatccg	5040
caatagaaat tgctcgacaa attaatactg	aaaaattcga tccgcaactac atcggaaatta	5100
caaaaaacgg cgtatggaa ctatgcaaga	agccatgtac ggaatggaa gccgatagtc	5160
tccccccat attctccccg gataggaaaa	cgcattgtct gttgtcatg aaagaaagag	5220
aatacgaaac tcggcgatt gacgtggctt	tcccggtttt gcatggcaaa tgcggggagg	5280
atggtgcgt acagggtctg ttgtattgt	ctggtatccc ctatgttagc tgcgatattc	5340
aaagctccgc agcttgcatt gacaaatcac	tggcctacat tcttacaaaa aatgcgggca	5400
tcggcgcccc cgaatttcaa atgattgaaa	agggtgacaa accggaggcg aggacgctta	5460
cctaccctgt ctttgtgaag ccggcacgg	cagggtcgctc ctttggcgta accaaagtaa	5520
acagtcgga agaactaac gctgcgtatg	aagcagcagg acaatatgtat gaaaaaatct	5580
taatttgcga agcgatttcg ggctgtgagg	tcggctgcgc ggtcatggga aacgaggatg	5640
atttgattgt cggcgaatgt gatcaaattcc	ggttgagcca cggatcttc cgcattccatc	5700
aggaaaaacga gcccggaaaaa ggctcagaga	atgcgtatgtatcgttcca gcagacattc	5760
cggtcgagga acgaaatcggt gtgcagaaaa	cggcaagaa agtataatcggt gtgcttggat	5820
gcagagggtc tgctcggtt gatctttttt	tgcaggagga tggcggcattc gttctaaacg	5880
aggtcaatac cctggccgtt ttacatcg	acagccgcta tccacgcatt gcggctgccc	5940
caggaatcac gcttcccga ctaattgaca	gcctgattac atttgcgata gagaggtgac	6000
ccgtatggaa aatgggtttt tgtttttaga	tgaaatgtt catgggttgc gttggatgc	6060
caagtacgt acatggata acttcacggg	aaaaccatgt gatgggtatg aggtgaatcg	6120
catcatcgcc acaaaggccg tggcgcttgc	tctgcgcgaa gcacaaatcc atgcggcacg	6180
ccttggctac ggcttgcattt tatggatgg	atatcgccca aaatctgcgg tggactgttt	6240
cctgcgttgg gcggcgacgc cggaggacaa	cctcacaaaa gaaaaatatt accccaatat	6300
tgagcgagcc gagttgatta caaagggtca	tgtggctca caatccagcc atagccgtgg	6360
aagcacaatt gatcttacgc tctaccactt	ggatacaggg gaactgtttt caatggaaag	6420
caacttcgat ttatggacg aacggtcgca	ccatacagca aaaggatag ggaatgcaga	6480
ggcacaaaaat cgaagatgt tgcgtaaaat	catggaaagc agcggatttc agtcctatcg	6540
ctttgaatgg tggcactata agttgattga	tgagccatac cccgatacctt attttaattt	6600
tgctgtttca taatgaaaatg atttgatttt	ctaattatgt ataagtggc tacaaattac	6660
tttagtatttc atcagaccaa ttactcttt	gtttacagaa aaattctgcg ctgatgaaat	6720
ctgctttatt atgcgggcga aaaatgaaat	tgaccatatt tttcagaac tttactctgt	6780
accgaattgc ctgcaaaagc cttatTTAA	gctgaaatgt caggaattgc tttgttttt	6840
gtgtatgccc ctcgtgattt gtacacccat	cttaattggc tttgcatttc tcattccgt	6900
tctctgtttt aagaatttgg aaaaacgaag	cattgtgaat cggctgcggg cagagcaaaa	6960
agagaaccag cagaaacaag tcgttcttgc	tctgcgtatt cactcggaaac ttttttattt	7020
gggttttgcgt tgaagggtcaa gtagctgctc	tgtcaggaag tccagtgtgt tcagcagaat	7080
ctgcgtatttgc acacgggttgc atgactgaaa	ttttccatg aaacgcgttga gttcttcatc	7140
ctcaatagag ttgtaaagctt		7160

<210> 3

<211> 1086

-7-

<212> DNA

<213> Enterococcus casseliflavus

<400> 3

gtaagaatcg	aaaaagcgga	aggaagaaaa	acatgaaaaa	aatcgccatt	attttggag	60
gcaattcacc	ggaatacacc	gtttcttag	cttcagcaac	tagcgcaatc	gaagcactcc	120
aatcatctcc	ctatgactac	gacctcttct	tgatcgggat	cgcggccagat	gctatggatt	180
ggtacttgta	tacaggagaa	ctggaaaaca	tccgacaaga	cacgtggttg	ttggatacga	240
aacataaaca	gaaaatacag	ccgctattcg	aaggaaacgg	cttttggcta	agtgaagagc	300
agcaaacgtt	ggtacctgtat	gttttatttc	ccattatgca	tggcaaaatac	ggggaaagatg	360
gcagtatcca	aggattgttt	gaattgtatga	agctgcctta	tgtaggctgc	ggggtggcag	420
gttctgcctt	atgtatgaac	aatggctgc	tgcataaggc	tgcagcagcc	attggcgtac	480
aaagtgcctc	tacgattctc	ttgacaaaatc	aagccaacca	gcaagaacaa	atcgaagctt	540
ttatccagac	ccatggcttc	ccagttttct	ttaagcctaa	tgaagcgggc	tcctcaaaag	600
ggatcactaa	agtcacctgc	gttgaagaaa	tcgccttcgc	cttaaaagaa	gcctttactt	660
attgttccgc	agtgcctta	caaaaaaata	ttgccgggtgt	tgagatcggt	tgcggatattt	720
tggccaacga	ctctttgact	gtcggtgctt	gtgacgcctat	tccatttagta	gacggctttt	780
tcgattttga	agaaaagtagc	cagctgatca	gcccacaaat	caccgtccct	gcccattgc	840
ctgaaacgt	tgaaccaag	gtcaaagaac	aagctcagct	gctctatcg	agtcttggc	900
ttaaaggct	tgcctcgatc	gacttttttg	tcacggagcg	aggagaacta	tacttgaatg	960
aaatcaatac	tatgccgggc	tttacgagtc	actcccgtt	tcctgcccatt	atggcagcgg	1020
tcggcttatac	ctatcaagaa	ctactacaaa	aactgctgt	cttagcaaaag	gaggaagtca	1080
aatgag						1086

<210> 4

<211> 5781

<212> DNA

<213> Enterococcus faecium

<400> 4

attaatctgc	attgttgttt	cataatcgatt	ttgacacata	ataaagacag	attatcgca	60
tgtaaggagt	aatgcataatg	atgaaaaaaat	cttagtgggt	gatgtgaaa	aagaattggc	120
cgacttagtt	gaagtataatc	tgaaaaaacga	tggatataacc	gtttataaaat	tttataatgg	180
caaggatgca	ctaaagtgtt	ttgaatccgt	ggaactggat	ttagccatat	tggatatcat	240
gcttcggat	gtagacgggt	ttcagatctg	ccagaaaaatc	cggggaaaatg	tttactttcc	300
tgttatcatg	ctgacagcaa	aagtggagga	cggggataaa	atcatggac	tgtccgtggc	360
ggatgattat	attacaaagc	cgtttaaccc	gctggaaatgt	gttgcgagag	taaaggcgc	420
gctgcggcag	tacatgcgg	acaaggcagcc	cagcttaaag	caggaggctg	aatgcacaga	480
atacgatatac	agagggatga	caatcagcaa	gaggcagccat	aagtgtatcc	tgtttggaaa	540
ggagattcag	ctgacgccaa	cgaggatttc	gattcttgg	tatctgtgc	agcgtcaggg	600
tacggttgtt	tctacggagg	aattatttga	ggcagttatgg	ggtgaacgg	tttttgacag	660
caataatact	gtgatggcgc	atatcgccg	gctccgggag	aaaatgaagg	aaccgtcaag	720
aaatccgaaa	tttataaaaaa	ctgtgtgggg	agtgggat	accattgaaa	aatagaata	780
aaaccagtca	tgaagatgac	tatattactt	ttaaaaacag	attgtccgtt	aaaatactgc	840
ttatgatggt	atattccatt	ctgattattt	cggtgtttt	tctgtttatc	ttaaaaagata	900
attttgcaaa	tgctgtggta	gccattttag	acagctttat	ctatcatgt	cgggatgagg	960
cggtgctgt	ttatctgaga	accttaagg	cgtctgagat	atggctttt	ctgatagcgg	1020
ttatggcgt	gtttttttag	atcttccgc	gttatctgga	cagtatttca	aaatatttta	1080
aggagatcaa	cggggggatc	gatactttgg	tgaatgagga	tgccaaacgt	attgggctgc	1140
ctccggagtt	ggcttcgacc	gaaagaaaaa	tcaattccat	acggcatacc	ctgacgaaac	1200
ggaaaaacgga	cgctgagct	gcagagcaa	ggaaaaacga	tcttgcata	tatctggccc	1260
atgacctgaa	gaccccgctt	ccatcggtca	taggatattt	gaacctgtt	agggatgaga	1320
atcagatttc	cgaggaactt	agggaaaaat	atttgcatt	atcattggat	aaggctgagc	1380
gtctggaaga	actgatataat	gagtttttg	aaattacgag	gtttaatctt	tcaaacatca	1440
cgcttgcgt	cagcaaaatc	aatctgacga	tgatgctgga	acagctgggg	tatgagttt	1500
agccgatgt	ggccggggaaa	aatctgaaat	gtgaatttga	tgttcagcca	gacatgatgc	1560
tgccctgcga	tgccaaacaag	ctgcagcggg	tcttcgataa	tgtgctgaga	aatgccgtca	1620

-8-

gctactgcta	tgagaataacc	accattcggg	tgaaaggccag	gcagaccgaa	gaccatgtac	1680
tcatcaaaat	cataaacgaa	ggggatacga	ttcctgggaa	gagattggaa	agaatcttg	1740
agcagtta	ccgcctggat	gtatctcgaa	gctcaagtac	cggcgcccc	ggtctgggc	1800
ttgcattgc	aaaagagatt	gtggaactgc	accatggaca	gatcaactgcc	cacagcgaaa	1860
atggtatcac	cagtttgag	gttacattgc	ccgtcgtagg	aaaatcgtaa	gaaattccga	1920
gataaacgt	gtgttatcca	taaaaagaacg	cgaaaacata	aatcgctcta	ttctggatg	1980
cttataatca	ggagggggcga	ttttttgtc	ttcagaaaagg	agtccagggt	aatgatggaa	2040
tatcaaaaca	ataatggaaa	ctatgacaaa	aggaatcgta	gaaaagccaa	aaaaagaaaa	2100
ttgcttttt	acagggctgc	atgtgtcaca	cttggggc	tcattgtttc	tgtaatctt	2160
ggagttgtgc	attttttagg	ggagagtaaa	gatcccggcc	tttatccaa	agaaaaacaca	2220
aaaacagaca	agaactattc	gtggcttacc	gacgatcaga	atgaggcagt	acccctcagtt	2280
ccagagccag	ccatatccga	ccaggctaac	aaaatttcgg	taaatatcac	agcggcaaac	2340
gccattgtaa	tgaataaaga	cacaaatgag	gtattgtacc	agaaaaaaaag	cacagccaa	2400
attgcgcgg	ccagcaactgc	taagatgatt	atggcttga	cagcacttga	ctattgtcc	2460
ccggaggatg	aaatgaaagt	aggtgcggag	attggaatga	ttcaaagcga	ttcgtaacc	2520
gcatggctta	tgaagggtga	tacactgact	gtcagacagc	tcctgattgc	ccttatgctt	2580
ccgtccggca	atgatgcagc	ctataccctt	gcagtcaata	ccggaaaggc	tattgcaggt	2640
gataacagcc	tgaccagtca	gcaagcgtatt	gaagtattca	tggataaggt	aatgaaaaa	2700
gccgtggccc	ttggcgccac	aaactcgaaa	ttttagtctc	cgatggata	tgatgcgaa	2760
gggcagtata	ctacagctt	tgaccttgc	atcattgca	aagcatgttt	ggacaatcct	2820
atcatattcg	agattgttagc	gagttattca	tcctatgaaa	aatggtcaaa	cggaagagag	2880
gtcaacttaca	acaattccaa	tgagcttctc	gatccgaaca	gtccctatta	ccgtccggag	2940
gttatecggt	tgaaaacagg	aaccagcagt	cttggggcg	catgtattgt	ttctgcagcg	3000
gtgatggacg	gagaaaccta	tatctgtgt	gttatgggtt	ctacaaagga	aagcaggttt	3060
caggacagcg	ttgatatttt	agataaaatc	aaagcccagt	aacgagataa	ggagggaaatg	3120
aatggagaaa	ataatagaca	taactgtttt	tggctgcgag	ccagacgaaa	tggaggttt	3180
tcaaaagatt	tcttatgagc	ttgtgttac	agccacactc	ataaaagatt	ctatattcaga	3240
aagcaatgct	ggattagcta	atggatgccg	gtgtgtta	gtaagccata	aageggagct	3300
atcagaaccg	atttttttgc	cgctaaaaaa	tgcaggggta	aaatatatca	gtacccggag	3360
cattggttt	aaccatattt	atatacaggc	ggctgggta	ctgggtatgg	ttgttgcac	3420
agtagaatac	tcgccccggaa	gtgtggccga	ttataccgtc	atgctgtatgc	ttatgtctat	3480
gcgtggcaca	aagtgcattc	tgcgtaaac	ccagaggcag	aattattgcc	tgaatgacct	3540
gcfgggaaaa	gaactgcggg	atatgaccgt	gggtgtgtt	ggaactgggc	gaatcgaca	3600
ggcagtcatg	gagcgcctgg	aggattcgg	ttgtaaaggta	ttggcgtatg	accgaaatca	3660
aaaacagcaga	gcagactatg	tttcgtttca	tgaactgtc	aaaaaaagtg	acattgttac	3720
actgcatac	ccgttggcg	aggatacccg	ccatatgatt	ggctatgaa	agctggaaat	3780
gatgaaggaa	gaggcgcctc	tgcataatac	agggcgcccc	gctttagtgg	ataccgcagc	3840
attggtagaa	gcattaaaag	gacagaaaaat	cgccggcgcc	ctggatgttt	tggaaaggcga	3900
agaaggatc	ttttaccatg	actgcaccca	aagaagaata	gaacatccctt	tcctgtcggt	3960
cctgcaggga	atgccaatg	tcattgttac	gccgcacaca	gcctatcata	cggaacgggt	4020
gttgggttgc	acggtcagaa	atactattag	aaattgttt	aattttgaaa	ggagtctggg	4080
aaatgtttag	aattaaagtt	gcagttctgt	ttgggggctg	ttcagagggaa	cataatgttt	4140
cgataaaatc	tgcgatggag	attggcccaa	acatagatac	aaaaaaatat	cagccttatt	4200
atattggaa	cacaaaatcc	ggcgttttgg	aaatgtgt	aaaaccttgt	ttggaggtgg	4260
aacaatatgc	gggggatccg	tttgggggg	cgccggacag	aagtacgcatt	ggtctgtga	4320
tacaaaaaga	caaagggtat	gaaatccagc	ctgtggatgt	ggtgtttccg	atgattcatg	4380
gcaagtttgg	ggaggatggc	ccatatacaag	gcttgcgttga	attgtcaggc	attccgtatg	4440
tgggatgcga	tattcaaaagc	tccgtatct	gcatggataa	ggcgcgttgc	tataccgtt	4500
tgaaaaatgc	gggtatcact	gtgcctgggt	tccggatct	tcaggagggg	gatgccttgg	4560
aaacggagga	tttcgtatata	ccgttttttgc	taaaggctgc	ccgttccggc	tcatccctt	4620
gcgtaaacaa	ggtatgcag	gcagaagaac	tgcaggcagc	aatcgaaagaa	gcaagaaaaat	4680
atgacagcaa	gattttgatt	gaagaggccg	ttaccggag	tgaggttagc	tgcgcatac	4740
tggaaacgg	aaatgatctc	atggctggcg	aggtggatca	gattgagctg	agacacggct	4800
tttttaagat	tcatcaggaa	gcacagccgg	agaagggatc	tgaaaatgc	gtcatccgag	4860
ttccagccgc	cttaccggat	gagtaagag	aacagattca	gaaaacggca	atgaagattt	4920
accggatact	tggctgcaga	ggattggccc	gcattgacct	ttttttgcgg	gaggacggtt	4980
gcattgtgt	aatgaaagt	aataccatgc	caggtttac	ttcctacagc	cgctatcccc	5040

-9-

gcatgatgac	agcagccggt	tttacgcttt	ctgaaataact	ggatcgcttg	attgaacttt	5100
cacttag gag	gtaactgtca	tgaaaaagaa	ctttgccttt	ttagatgaaa	tgattcccg	5160
gatccgatgg	gatgccaaat	atgcccacctg	ggacaattc	accggaaaac	cggtagacgg	5220
atacatggta	aaccgttta	tgggaacgaa	ggagctggga	gttgc ttgc	gtaaggctca	5280
gaagatggcg	gagaagctag	gatatggttt	gctttatgg	gacggctatc	gccccca gtg	5340
cgcagtgaat	tgttttctga	attgggcttc	ccaaccgaa	gacaatctga	cgaaaaaagcg	5400
ttactatcca	aatatcaaaa	ggaatgagat	ggttgcgaag	gggtatgtgg	cctcacaatc	5460
cagccacagc	cgttggaa gta	cggttgcacct	tacaattttt	catttgaata	gcggtatgct	5520
tgttccatg	ggtggagatt	ttgactttat	ggatgaacgg	tcacaccatg	ccgcaagcg	5580
tctgagcgaa	gaagaatcaa	aaaaccggca	gtgcttgcgt	tatatcatgg	agagtagcg	5640
at ttaa gec	tatcgttatg	aatgg tggca	ttacgttttgc	g cggacgagc	cata acccgga	5700
tacatatttt	gat ttttgc a	ttgccttagt g	agagcctgaa	gaaatgaaa a	atgtaagatt	5760
ataaggacaa	gcggcatgag	g				5781

<210> 5
<211> 27
<212> DNA
<213> Enterococcus faecium

<400> 5
gg tggcgcgg gacttggatg gcgattg 27

<210> 6
<211> 30
<212> DNA
<213> Enterococcus faecium.

<400> 6
ggcgcggatg attatataac gaagcccttt 30

<210> 7
<211> 18
<212> DNA
<213> Enterococcus faecium

<400> 7
cgagccggaa aaaggctc 18

<210> 8
<211> 20
<212> DNA
<213> Enterococcus faecium

<400> 8
ggctgcgata ttcaaagctc 20

<210> 9
<211> 27
<212> DNA
<213> Enterococcus faecium

<400> 9
attactgttt atggatgtga gcaggat 27

<210> 10

-10-

<211> 26
<212> DNA
<213> Enterococcus faecium

<400> 10
gtggcttcaa aatcaagcca tagccg 26

<210> 11
<211> 18
<212> DNA
<213> Enterococcus casseliflavus

<400> 11
cgagccggaa aaaggctc 18

<210> 12
<211> 20
<212> DNA
<213> Enterococcus casseliflavus

<400> 12
ggctgcgata ttcaaagctc 20

<210> 13
<211> 20
<212> DNA
<213> Enterococcus faecium

<400> 13
ggctgcgata ttcaaagctc 20

<210> 14
<211> 30
<212> DNA
<213> Enterococcus faecium

<400> 14
cuacuacuac uacgattca agaacactgg 30

<210> 15
<211> 36
<212> DNA
<213> Enterococcus faecium

<400> 15
caucaucauc auccaaccct ttctgtaaa ggcacc 36

<210> 16
<211> 38
<212> DNA
<213> Enterococcus faecium

<400> 16
cuacuacuac uactcgaggc ttatcacccc tttaacgc 38

<210> 17
<211> 32

-11-

<212> DNA		
<213> Enterococcus faecium		
<400> 17		
caucaucauc auggagacag gagcatgaat ag		32
<210> 18		
<211> 696		
<212> DNA		
<213> Enterococcus faecium		
<400> 18		
atgagcgata aaatacttat tggatgtat gaacatgaaa ttggccgattt ggttgaatta 60 tacttaaaaa acgagaatta tacggtttc aaatactata cgcggaa 120 tgtatagaca agtctgagat tgacccctgc atattggaca tcattgttcc cgccacaaggc 180 ggccttacta tctgtcaaaa aataaggggac aagcacacct atccgattat catgtgacc 240 gggaaagata cagaggtaga taaaattaca gggtaacaa tcggcgccgg tgattatata 300 acgaagccct ttcgcccact ggagtttaatt gctcgggtaa aggcccagt ggcggataac 360 aaaaaaattca gtggagtaaa ggagcagaac gaaaatgtt tcgtccactc cgcccttg 420 attaatgtt acaccatga gtgttatctg aacgagaagc agttatccct tactcccacc 480 gagtttcaa tactgcaat cctctgtgaa aacaaggggg atgtggtag ctccgagctg 540 ctatattcatg agatatgggg cgacgaatat ttcagcaaga gcaacaacac catcaccgtg 600 catatccgca atttgcgcga aaaaatgaac gacaccattt gataatccgaa atatataaaa 660 acggtatggg gggttggta taaaattgaa aaataa 696		
<210> 19		
<211> 1155		
<212> DNA		
<213> Enterococcus faecium		
<400> 19		
ttggttataa aattgaaaaa taaaaaaaaac gactattcca aactagaacg aaaactttac 60 atgtatatcg ttgcaattgt tggatgtatca attgtattcg tggatgtatat tcgttcaatg 120 atccgaggga aacttggga ttggatctta agtattttgg aaaacaaaata tgacttaat 180 cacctggacg cgatgaaatt atatcaatat tccatacgga acaaatataga tatctttatt 240 tatgtggcga ttgtcattag tattcttatt ctatgtcgcg tcattgttcc aaaattcgca 300 aaatactttg acgagataaa taccggcatt gatgtactta ttcagaacga agataaaca 360 attgagctt ctgcggaaat ggatgtttagt gaacaaaacg toaacacatt aaaacggact 420 ctgaaaaagc gagagcagga tgcaaaagctg gccgaacaaa gaaaaaatga cggtttatg 480 tacccggcgc acgatattaa aacgccccctt acatccatta tcggatattt gagcctgctt 540 gacgaggctc cagacatgcc ggttagatcaa aaggcaaaatg atgtgcataat cacgttggac 600 aaagcgtatc gactcgaaaca gctaatcgac gagtttttg agattacacg gtataaccta 660 caaacgataa cgctaacaaa aacgcacata gacctataat atatgtggt gcagatgacc 720 gatgaatttt atccctcagct ttccgcacat gggaaacagg cggttattca cgcccccgag 780 gatctgaccg tggccggcga ccctgataaa ctcgcgagag tctttaacaa cattttgaaa 840 aacggccctg catacagtga ggataacacg atcattgaca ttaccgggg cctctccggg 900 gatgtgggtt caatcgaaatt caagaacact ggaagcatcc caaaagataa gctagctgcc 960 atatttggaa agttctatag gctggacaat gctcggttcc ccgatacggg tggcgccggaa 1020 cttggattgg cgattgcaaa agaaaattatt gttcagcatg gagggcagat ttacgcccggaa 1080 agcaatgata actatacgac gtttaggta gagcttccag cgatgccaga cttgggtttagt 1140 aaaaggaggt cctaa 1155		
<210> 20		
<211> 969		
<212> DNA		
<213> Enterococcus faecium		

-12-

<400> 20	atgaataaaca tcggcattac tgtttatgga tggcgttcagg atgaggcaga tgcattccat	60
gctcttcgc ctcgctttgg cgttatggca acgataatta acgccaacgt gtcggaatcc	120	
aacgc当地at ccgcgc当地tta caatcaatgt atcagtggtgg gacataaaatc agagatttcc	180	
gcctcttattc ttcttgcgct gaagagagcc ggtgtgaaat atatcttctac ccgaagcatac	240	
ggctgcaatc atatacgatc aactgctgct aagagaatgg gcatactgt cgacaaatgtg	300	
gcgtactcgc cggatagcgt tgccgattat actatgatgc taatttcttata ggcagtacgc	360	
aacgtaaaat cgattgtgcg ctctgtggaa aaacatgatt tcaggttggaa cagcgcaccgt	420	
ggcaaggatc tcagcgacat gacagtttgtt gttgtggaa cggccagat aggcaaagcg	480	
gttattgagc ggctgctgagg atttggatgt aaagtgttgg ttatatacgatc cagccgaagt	540	
atagaggtaa actatgtacc gtttgcgttggaa atagcgatata cgttacgcctt	600	
catgtgccgc tcaatacggg tacgcactat attatcagcc acgaacaaat acagagaatg	660	
aagcaaggag catttcttata caataactggg cgcggccac ttgttagatac ctatgagttg	720	
gttaaaagcat tagaaaaacgg gaaactgggc ggtgcccata tggatgtatt ggaaggagag	780	
gaagagttt tctactctga ttgcacccaa aaaccaatttgcataatcaatt ttactttaaa	840	
cttcaaaagaa tgccataacgt gataatcaca ccgcatacgg cctattatac cgagcaagcg	900	
ttgcgtgata ccgttgaaaa aaccattaaa aactgtttgg attttggaaag gagacaggag	960	
catqaatacg	969	

```
<210> 21
<211> 1032
<212> DNA
<213> Enterococcus faecium
```

<400> 21						
atgaatagaa	taaaaaggttgc	aatactgttt	ggggggttgct	cagaggagca	tgacgtatcg	60
gtaaaaatctg	caatagagat	agccgctaac	attaataaaag	aaaaaatacga	gccgttatac	120
atggaaatta	cgaatctgg	tgtatggaaa	atgtgcgaaa	aaccttcgcgc	ggaatgggaa	180
aacgcacaatt	gctattcagc	tgtactctcg	ccggataaaaa	aatatgcacgg	attacttgg	240
aaaaagaacc	atgaatatga	aatcaaccat	gtttagttag	cattttcagc	tttgcattggc	300
aagtccagg	tg aagatggatc	catacaaggt	ctgtttgaat	tgtccgttat	cccttttgc	360
ggctgcgata	ttcaaagctc	agcaatttgt	atggacaaaat	cggtgacata	catcggtcg	420
aaaaatgctg	ggatagctac	tcccgccctt	tgggttattt	ataaaagatga	taggcccgtg	480
gcagctacgt	ttaccttatcc	tgtttttgtt	aagccggcgc	gttcaggctc	atcccttcgg	540
gtgaaaaaaag	tcaatagcgc	ggacgaattt	gactacgcaa	ttgaatccgc	aagacaaat	600
gacagcaaaa	tcttaattga	gcaggctgtt	tccggctgtg	aggtcgggtt	tgcggatttg	660
ggaaaacagt	cccgcttagt	tgttggcgag	gtggacaaa	tcaggctgca	gtacggaaatc	720
tttcgttattc	atcaggaagt	cgagccggaa	aaaggctctg	aaaacgcagt	tataaccgtt	780
cccgccagacc	tttcagcaga	ggagcgagga	cgatatacagg	aaacggcaaa	aaaaatataat	840
aaagcgctcg	gtgttagagg	tctagccccgt	gtggatatgt	ttttacaaga	taacggccgc	900
attgtactga	acgaagtcaa	tactctgtccc	ggtttcacgt	catacagtcg	ttatccccgt	960
atgatggcccg	ctgcaggat	tgcacttccc	gaactgattt	accgcttgat	cgtattagcg	1020
ttaaagggtt	ga					1032

<210> 22
<211> 609
<212> DNA
<213> Enterococcus faecium

<400> 22						
atggaaatag	gatttacttt	tttagatgaa	atagtacacg	gtgttcgttg	ggacgctaaa	60
tatgccactt	gggataattt	caccggaaaa	cccggttgacg	gttatgaagt	aatatcgcat	120
gtagggacat	acgagttggc	tgaatcgctt	ttgaaggcaa	aagaactggc	tgctacccaa	180
gggtacggat	tgcttctatg	ggacggttac	cgtcctaagc	gtgctgtaaa	ctgttttatg	240
caatgggctg	cacagccgga	aaataacctg	acaaaggaaa	gttattatcc	caatattgac	300
cgaactgaga	tgatttcaaa	aggatacgtg	gcttcaaaat	caagccatag	ccgcggcagt	360
gccattgtatc	ttacgcttta	tcgattagac	acgggtgagc	ttgttaccaat	ggggagccga	420

-13-

tttgattta tggatgaacg ctctcatcat gcggcaaatg gaatatcatg caatgaagcg	480
caaaaatcgca gacgttgcg ctccatcatg gaaaacagtg ggtttgaagc atatagcctc	540
gaatggtggc actatgtatt aagagacgaa ccataccccca atagctattt tgatttcccc	600
gttcaaataa	609

<210> 23
 <211> 912
 <212> DNA
 <213> Enterococcus faecium

<400> 23	
atgaagaagt tgttttttt attgttattt ttattcttaa tatacttagg ttatgactac	60
gttaatgaag cactgtttt tcaggaaaaa gtcgaatttcaaaaattatga tcaaaaatccc	120
aaagaacatt tagaaaatag tggacttct gaaaataccc aagagaaaaac aattacagaa	180
gaacagggtt atcaaggaaa tctgcttta atcaatagta aatatcctgt tcgccaagaa	240
agtgtgaagt cagatatcgt gaatttatct aaacatgacg aattaataaa tggatacggg	300
ttgcttgata gtaatattta tatgtcaaaa gaaatagcac aaaaattttc agagatggc	360
aatgatgctg taaagggtgg ctttgcatttttatttata atagtggcta tcgagacttt	420
gatgagcaaa gtgtgcctta ccaagaaaatggggctgagt atgccttacc agcagggtt	480
agtgagcata attcagggtt atcactagat gtaggatcaa gcttgcacaa aatggAACGA	540
gcccctgaag gaaagtggat agaagaaaaat gcttggaaat acgggttcat tttacgtt	600
ccagaggaca aaacagagtt aacaggaatt caatatgaac catggcatat tcgctatgtt	660
ggtttaccac atagtgcgtatgaaagaa aagaatttcg ttctcgagga atatatggat	720
tacctaaaag aagaaaaaac catttctgtt agtgtaaaatggaaaaata tgagatctt	780
tattatcctg ttactaaaaa taccaccatt catgtgccga ctaatctcg ttatgagata	840
tcaggaaaca atatagacgg tctaattgtg acagtgttc ccggatcaac acataactaat	900
tcaaggaggtt aa	912

<210> 24
 <211> 486
 <212> DNA
 <213> Enterococcus faecium

<400> 24	
ttggaaaaaa tattatcttag aggattgcta gctttatatt tagtgacact aatctggta	60
gtgttattca aattacaata caatattta tcagttttt attatcatca aagaagtctt	120
aacttgactc catttactgc tactggaaat ttcagagaga tgatagataa tggtataatc	180
tttattccat ttggcttgct ttgtatgtc aattttaaag aatctggatt ttacctaag	240
tttgcttttgc tactgggttt aagtcttact ttgtatgtc aattttaaat ttcaattttat ctgcgtt	300
ggagcgacag acataacaga tgtaattaca aatactgtt gaggcttct tggactgaaa	360
ttatatggtt taagcaataa gcatatgaat caaaaaaaaaat tagacagagt tattatgtt	420
gtaggtatac ttttgcgtt attattgtc gtttacgtt cccatattaag aataaattac	480
gtgtaa	486

<210> 25
 <211> 19
 <212> DNA
 <213> Enterococcus faecium

<400> 25	
cgaataccgc aagcgacag	19

<210> 26
 <211> 663
 <212> DNA
 <213> Enterococcus faecium

-14-

<400> 26

atgtcgatac gaattctact tgtcgaggat gatgatcata tctgcaatac agtaagggcg	60
tttttggctg aagcaagata tgaggtggat gcctgcacag atggaaacga agcacacacc	120
aagtctatg aaaacaccta tcaactgggtt attcttgata ttatgctgcc cggtatgaat	180
gggcatgaac ttctacgtga atttcgggchg caaaatgata ccccccattct gatgatgaca	240
gccctgtcgg atgacgaaaa ccaaattccgg gcgtttatg cagaggcaga cgactatgta	300
acaaaagccat tcaagatgctg gattttacta aagcgggtgg aagccctgtt acggcgcage	360
ggtgtcgctgg caaaggaatt tcgtgtggc aggctgacac ttctgcccggg ggattttagg	420
gtactttgtg acggtacgga gctgccccctg acacgaaaag aatttgaat cctttgctg	480
ctgggtgcaga acaaaggcag aacctaacc catgaaatca ttttgcctccg catatggga	540
tatgactttg acggtatgg cagcacagtc cacactcata tcaaaaaatct gcggggcgaag	600
ctgcccggaaa atatcatcaa aaccatccgc ggttaggtt accgatttgg ggaatcatta	660
taa	663

<210> 27

<211> 1344

<212> DNA

<213> Enterococcus faecium

<400> 27

atggaaagaa aagggatttt cattaagggtt ttttcctata cgatcattgt cctgttactg	60
cttgcggctg taacggcaac actgtttgca cagcaatttg tgtcttattt cagagcgatg	120
gaagcacagc aaacagtaaa atcctatcag ccattgggtgg aactgattca gaatagcgat	180
aggcttgcata tgcaagaggt ggcagggtcg tttcactaca ataaccaatc cttttagttt	240
tatattgaag ataaagaggg aagcgtactc tatgccacac cgaatgccga tacatcaaat	300
agtgttaggc ccgactttct ttatgtggta catagagatg ataataatttc gattttgtct	360
caaagcaagg caggtgtggg attgcttat caagggtctga caattcgggg aattttatg	420
attgc ataa tggttgtatt cagccttttgcgcgtata tcttgcgcgc gcaaattgaca	480
acgcccgtatca aagccttagc ggacagtgcg aataaaatgg caaacctgaa agaagtaccg	540
ccgcccgtgg agcgaaagga ttagcttggc gcactggctc acgacatgca ttccatgtat	600
atcaggctga aagaaaccat cgcaaggctg gaggatgaaa tcgcaaggga acatgatgtt	660
gaggaaacac agcgatattt ctttgcggca gcctctcatg agttaaaaac gcccattcg	720
gctgttaagcg ttctgttggaa ggaatgttt gaaaatatcg gtgactacaa agaccattct	780
aagtatctgc gcgaatgtatca aaaaatgtatg gacaggcagg gcaaaaccat ttccgaaata	840
ctggagcttgc ttagcttgcgat cgttggaga atcgttacca tagccgaacc gctggacata	900
ggggcgacgg ttggcgagct gctacccgt tttcaaacct tggcagaggc aaacaaccag	960
cgggttcgtca cagatattcc agccggacaa attgttctgt ccgttccgaa gctgtatccaa	1020
aaggcgctat ccaatgtcat attgaatgcg gttcagaaca cggcccgagg aggtgaggta	1080
cgatgtatggaa gtgagctgg ggctaaaaaa taccgtttt ccgttttggaa catggcggtt	1140
cacattgtatc atactgcact ttcaaaagctg ttcatccat tctatcgat tgatcaggcg	1200
cgaaggcagaa aaagtggcg aagcggtttgg gggcttgcata tcgtacaaaa aacgctggat	1260
gccatgagcc tccaatatgc gctggaaaac acctcagatg gctttttgtt ctggctggat	1320
ttaccggccca catcaacact ataa	1344

<210> 28

<211> 807

<212> DNA

<213> Enterococcus faecium

<400> 28

atggaaaaaaa gcaactatca ttccaatgtg aatcatcaca aacggcatat gaaacaatct	60
ggggaaaaac gggctttctt atggggcttc attatctcg tcaacgtctg cacgtgtttt	120
ttgggggtggaa gattgggttc cgattggag gcaacacacgc taccggccat ccctgcaact	180
catacaggca gggggactgg ttagcgagg aatccagagg aaaacactct tgccaccgccc	240
aaagaacagg gagatgaaca ggaatggcgc ctgatttttag tgaacaggca gaacccatc	300
cccgccccagt acgatgtggaa acttggcgcg ctgtcaaatg gtgagcggat agacattcg	360
atttctccctt acctccaggaa tttgtttat gccgcaagag ctgatggagt ttacccgatt	420

-15-

gtcgcatccg gataccggac aacagaaaaaa cagcaagaaa tcatggatga aaaagtgcgc	480
gaatacacaagg cgaaaggcta cacctctgca caggctaaag cggaagcaga aacttgggtg	540
gccgtgcgg gaacaagcga gcatcagctt ggtcttgctg tggatatcaa tgcggatgga	600
attcattcaa ccggcaacga gtttacaga tggctggatg aaaacagcta tcgcttggt	660
tttattcgcc gctaccgc agacaagaca gagataaccg gtgtgagcaa cgagcgtgg	720
cattaccgat atgtcgcac cgaagctgcc acaaagatat accaccaagg gctttgcctt	780
gaggaatatt taaacacaga aaaaatga	807
<210> 29	
<211> 972	
<212> DNA	
<213> Enterococcus faecium	
<400> 29	
atgagaaaaaa gtatggcat tactgtttt ggatgcgagc aggatgaggc aaatgcttc	60
cgcacccat caccagattt tcatattatc cctacgctga tcagtgtatgc gatatcgca	120
gacaacgc当地 aattggccgc tggcaatcaa tgcattagcg taggcccataa gtccgagggtt	180
tccgaggcga caattcttgc gctgagaaag gtcggggtaa aatacatttc tacccgcagc	240
atccgctgca atcacattga tacgactgcc gccgagagaa tggggatctc ggttggcaca	300
gttgcgtatt cgccggacag cgttgcggat tatgcttga tgctgtatgc gatggccata	360
cggggtgcaa agtccaccat acacgcgtg ggcacacaaa attcagact ggattgtgtc	420
cgggggaaag agctgcggga tatgactgtg ggagttattt gAACCGGCA tataggc当地	480
gcggcgtca aaaggctgcg gggatttggg tgcgtgtgc tagcctatga taacagccga	540
aaaattgagg cagattatgt ccagcttgcgat gagcttctaa aaaacagcga tattgttacg	600
ctccatgtgc cgcttgcg ggtacccgc catctgatec gccagagcga aatcggagag	660
atgaagcaag gcgcattttt aatcaacact gggcgccccg cgttgcgcg taccgggtcg	720
ctgggtggagg cactgggaag cgaaaagctg ggcggcggg cactggatgt gttggaggc	780
gaggatcgt ttgttatac cgactgctcg cagaaagtgc ttgaccatcc cttttgcg	840
cagctctaa ggatgc当地 tgcgtatcat acacccata cggcgtacta caccgagcgt	900
gtgcgtgc当地 ataccacaga aaaaacaatc aggaattgtc ttaacttgc aaggagttt	960
cagcatgaat aa	972
<210> 30	
<211> 1029	
<212> DNA	
<213> Enterococcus faecium	
<400> 30	
atgaataaaaaaaa taaaagtgc当地 aattatctt ggcgggtgct cggaggaaca tgcgtgtcg	60
gtaaaatccg caatagaaaat tgctgc当地 attaatactg aaaaattcga tccgcactac	120
atcggatta caaaaaacgg cgtatggaaat ctatgc当地 agccatgtac ggaatggaa	180
gccgatagtc tccccgc当地 atttccccg gataggaaaaa cgc当地 ggtct gcttgc当地	240
aaagaaaagag aatacgc当地 tcggcgtatt gacgtggctt tcccggtttt gcatggc当地	300
tgcggggagg atggc当地 gcatgc当地 acagggtctg tttgaattgt ctggatccc ctatgttaggc	360
tgc当地 gatattc aaagctccgc agctgc当地 gacaaatc当地 tggcctacat tcttacaaaa	420
aatgc当地 gggca tcgccc当地 cgaatttcaat atgattgaaa aagggtgacaa accggaggcg	480
aggacgctt当地 cttaccctgt ctttgc当地 aga cccgc当地 cggc当地 acggc当地	540
acccaaagtaa acagtacgga agaactaaac gctgc当地 atagc当地 acggc当地 acaatatgt	600
ggaaaaatct taattgc当地 agc当地 gatttcg ggctgtgagg tggc当地 ggc当地 ggtc当地 atgggaa	660
aacgaggatg atttgc当地 tggc当地 aggtcaatcc gatcaatcc ggttgc当地 cggt当地 atcttcc	720
cgc当地 atccatc aggaaaacga gccc当地 aaaa ggctc当地 agaga atgc当地 atgtcc	780
gc当地 gagatcc cggc当地 gagga acgaaaatcg gtc当地 agaaaa cggc当地 aaaa agtataatcg	840
gtgc当地 tggat gc当地 gagggct tgc当地 gtgtt gatctt当地 tgc当地 gagggta tggc当地 gatc	900
gttctaaacg aggtcaatcc ctttgc当地 cggc当地 tttacatcg acagccgctt tccacgc当地	960
gc当地 ggctgccc当地 caggaatc当地 gcttccc当地 ctaattgaca gcctgattac attggc当地 gata	1020
gagaggta	1029

-16-

<210> 31		
<211> 609		
<212> DNA		
<213> Enterococcus faecium		
<400> 31		
atggaaaatg gtttttgtt tttagatgaa atgttgcatt gtgttcgttg ggatgccaag	60	
tacgctacat gggataactt cacggggaaaa ccagtggatg ggtatgaggt gaatcgcatc	120	
atccggcacaa aggccgtggc gcttgcctcg cgcaagcac aaatccatgc ggcacgcctt	180	
ggctacggct tgctttatg ggatggatat cggccaaaat ctgcgggtgga ctgtttcctg	240	
cgttggcgg cgccaggcggg ggacaaccc acaaaagaaa aatattaccc caatattgag	300	
cgagccgagt tgattacaaa gggctatgtg gcctcacaat ccagccatag ccgtggaagc	360	
acaattgatc ttacgcctta ccacttggat acagggaaac ttgtttcaat gggaaagcaac	420	
ttcgattttt tggacgaacg gtcgcaccat acagccaaaag ggatagggaa tgcagaggca	480	
caaatacgaa gatgcttgcg taaaatcatg gaaaggcagcg gatttcagtc ctatcgctt	540	
aatgggtggc actataagtt gattgatgag ccataccccg atacctattt taattttgt	600	
gtttcataaa	609	
<210> 32		
<211> 828		
<212> DNA		
<213> Enterococcus faecium		
<400> 32		
atgaacagaa aaagattgac acagcgcttc ccgttccctgc ttccaatgag acaagcgcag	60	
agaaaaatat gcttttatgc gggaaatgaga tttgacggct gttgctatgc acagacgata	120	
ggagaaaaaa cgcttcccta tttgctctt gaaacggatt gtgcgttata caaccacaat	180	
accggatttg acatgatata ccaagaaaac aagggttca acttaaagct ggccggcaaag	240	
accttaaacg gcctattgtt aaaaacgggg gaaacccccc ctttctggcg gctggtacgc	300	
catcgccgaca aagataaaaa ctataaaagac ggccttacgg tggccaatgg taagctcacc	360	
accatgtcgg gcccgggtat gtgccagatg agcaatttac tattttgggt gttccctgcatt	420	
acgccattga caatttatcca ggcgcagcggt cacgtatcaa aggagttcc agagccaaac	480	
atgtacgaga tcaaagggtt ggatgcaacc atctcagagg gctggattga tttaaaaagtg	540	
cgaaacgata ccgactgcac ctacccaaata tgggtgaccc tagatgatga gaaaatcatc	600	
ggtcaggtgt tcgcccacaa acagcctcaa gcattataca aaattgcaaa cggcagttt	660	
cagtatgtcc gtgaaagtgg cgggattttt gaatatgcca aggttgaacg gatgcaagtt	720	
gccttagtta ccggggaaat aatagattgc aagctgctt atacaaacaa atgcaaaaatc	780	
tgttatcccc tcccgaaaag tgtggatatt caggaggcga accaatga	828	
<210> 33		
<211> 1053		
<212> DNA		
<213> Enterococcus casseliflavus		
<400> 33		
atggaaaaaaa tcgcccattat ttttggaggc aattcacccgg aatacacccgt ttcttttagct	60	
tca gcaacta gcgcaatcga agcactccaa tcacatccct atgactacga cctctctttg	120	
atccggatcg ccccaagatgc tatggattgg tacttgtata caggagaact ggaaaaacatc	180	
cgacaagaca cgtgggtgtt ggatacgaaa cataaacaga aaatacagcc gctattcgaa	240	
ggaaaacggct tttggctaaag tgaagagcag caaacgttgg tacctgatgt ttatccccc	300	
attatgcattt gcaaaatcgg ggaagatggc agtaccaag gattgtttga attgatgaag	360	
ctgccttattt taggctgcgg ggtggcagg tctgccttattt gtatgacaaa atggctgctg	420	
catcaagctg cagcagccat tggcgtacaa agtgcctta cgattctttt gacaaatcaa	480	
gccaaccaggc aagaacaaat cgaagctttt atccagaccc atggcttccc agtttcttt	540	
aaggcctaattt aagcgggctc ctcaaaaggg atcactaaag tcacctgcgt tgaagaaatc	600	
gcttctgcct taaaagaagg ctttactttt tgttccgcag tgctcctaca aaaaaatattt	660	
gccgggtttt agatcggttg cggttattttt ggcaacgcact ctttgactgt cggtgcttgc	720	

-17-

gacgccattt cattagtaga cggtttttc gatttgaag aaaagtacca gctgatcagc	780
gccaaaatca ccgtccctgc gccattgcct gaaacgattg aaaccaaggt caaagaacaa	840
gctcagctgc tctatcgtag tcctggctt aaaggtctt ctcgcacatca ctccccgtc	900
acggagcgag gagaactata ctgaaatgaa atcaatacta tgccgggctt tacgagtcac	960
tcccgctatc ctgcccgtat ggcagcggtc ggcttatcct atcaagaact actacaaaaa	1020
ctgcttgtct tagcaaagga ggaagtcaaa tga	1053

<210> 34
<211> 699
<212> DNA
<213> Enterococcus faecium

<400> 34	
atgaatgaaa aaatcttagt gggtgatgat gaaaaagaat tggccgactt agttgaagta	60
tatctgaaaa acgatggata taccgttat aaattttata atggcaagga tgcactaaag	120
tgtattgaat ccgtgaaact ggatttagcc atattggata tcattgttcc ggtatgttagac	180
gggtttcaga tctgccagaa aatccggaa aagttttact tcctgttata catgctgaca	240
gcaaaaagtgg aggacgggaa taaaatcatg ggactgtccg tggcggatga ttatattaca	300
aaggcgttta acccgcttga agtggttgcg agagtaaagg cgccagctgcg gcagtcacatg	360
cggtacaagc agccccagctt aaagcaggag gctgaatgca cagaatacga tatcagaggg	420
atgacaatca gcaagagcag ccataagtgt atcctgtttg gaaaggagat tcagctgacg	480
ccaaacggagt ttccgttct ttggtatctg tgcgagcgtc agggtacggg tgggttctacg	540
gaggaattat ttgaggcagt atgggggtgaa cgggttttg acagcaataa tactgtgatg	600
gcgcataatcg ggccgctccg ggagaaaaatg aaggaaccgt caagaaatcc gaaatttata	660
aaaactgtgt ggggagtgaa atataccatt gaaaaatag	699

<210> 35
<211> 1146
<212> DNA
<213> Enterococcus faecium

<400> 35	
ttgaaaaata gaaataaaac cagtcatttgc gatgactatt tactttttaa aaacagattt	60
tccgttaaaa tactgcttata gatggatata tccattctga ttattgcggg tgggttatctg	120
tttatcttaa aagataattt tgccaaatgtc gtggtagcca ttttagacag ctttatctat	180
catgatcggg atgaggcggt ggctgtttat ctgagaacct ttaaggcgtc tgagatatgg	240
cttttcttgc tagcggttat gggcggttt tttatgtatc tccgcgttta tctggacagt	300
atttcaaaat attttaagga gatcaaccgg gggatcgata ctttggtgaa tgaggatgcc	360
aacgatattt ggctgcctcc ggagttggct tcgaccggaa gaaaaatcaa ttccatcacgg	420
cataccctga cgaaacggaa aacggacgct gagcttgcag agcaaaaggaa aaacgatctt	480
gtcatgtatc tggcccatga cctgaagacc ccgtttccat cggcgtatagg atatttgaac	540
ctgttaaggg atgagaatca gatttccgag gaacttaggg aaaaatattt gtccatata	600
ttggataagg ctgagcgtct ggaagaactg attaatgagt tttttgaaat tacgagggttt	660
aatctttcaa acatcacgt tttgtacagc aaaatcaatc tgacgtatgat gctggAACAG	720
ctggggatgt agtttaagcc gatgtggcc gggaaaaatc tgaaatgtga atttgtatgtt	780
cagccagaca tgatgtgtc ctgcgtatgcc aacaagctgc agcgggtctt cgataatgtq	840
ctgagaaatg ccgtcagcta ctgttatgag aataccacca ttccgggtgaa agccaggcag	900
accgaagacc atgttacatc caaaatcata aacgaagggg atacgattcc tggggagaga	960
ttggaaagaa tctttgagca gtttaccgc ctggatgtat ctgcgtatgctc aagtaccggc	1020
ggggccggc tggggcttgc cattgcaaaa gagattgtgg aactgcacca tggacagatc	1080
actgcccaca gcgaaaatgg tatcaccagt tttgaggatcatttgcgtc cgttaggaaaa	1140
tcgtaa	1146

<210> 36
<211> 1071
<212> DNA
<213> Enterococcus faecium

-18-

<400> 36

atgatggaat atcaaaaaca taatggaaac tatgacaaaa ggaatcgtag	aaaagccaaa	60
aaaagaaaaat tgctttta caggcgtca tgcgtcacac ttgtttgtc	cattgttct	120
gtaatctttg gagttgtca ttttttaggg gagagtaaag atcccggct	tttatccaaa	180
gaaaacacaa aaacagacaa gaactattcg tggcttaccg acgatcaga	tgaggcagta	240
ccctcagttc cagagccagc catatccgac caggctaaca aaatttcgg	aaatatcaca	300
goggcaaact ccattgtat gaataaagac acaaattgagg tattgtacca	gaaaaaaaaagc	360
acagccaaaa ttgcggccgc cagcactgct aagatgatta tggcttgc	agcacttgac	420
tattgttccc cggaggatga aatgaaaatg ggtgcggaga ttgaaatgat	tcaaagcgat	480
tgcgtcaaccg catggcttat gaagggtgat acactgactg ttagacagct	cctgattgcc	540
cttatgcgttc cgtccggcaa ttagtgcagcc tataccctt cagtcaatac	cggaaaggct	600
atgcagggtg ataacacgcct gaccagtcg caagcgattt aagtattcat	ggataaggta	660
aatgaaaaag ccgtggccct tggcgccaca aactcgaaat ttgtagctcc	ggatggat	720
gatgcccgaag ggcagtatac tacagctt gacctgtca tcattgc	aaaggat	780
gacaatccta tcatttcgga gattgttagcg agttattcat cctatgaaaa	atggtcaaac	840
ggaagagagg tcacttacaa caattccat gagctctcg atccgaacag	tccctattac	900
cgtccggagg ttatcggtt gaaaacagga accagcagtc ttggcggcgc	atgtattgtt	960
tctgcagcgg ttagtggacgg agaaacctat atctgtgtat ttatgggttc	tacaaaggaa	1020
agcaggtttc aggacagcgt ttagtattta gataaaatca aagcccagta	a	1071

<210> 37

<211> 969

<212> DNA

<213> Enterococcus faecium

<400> 37

atggagaaaa taatagacat aactgtttt ggctgcgagc	caacgaaaat ggaggtttt	60
caaaagattt cttatgagct tgggttaca gccacactca	taaaagattt tataatcagaa	120
agcaatgctg gattagctaa tggatgccgg tggtaagcg	taagccataa agcggagcta	180
tcagaaccga ttcttcttc gctaaaaat gcaggggtaa	aatatatcag taccggagc	240
attggttta accatattga tatacaggcg gctgggttac	tgggtatggt tggcaca	300
gtagaataact cgccggaaag tggccgtat tataccgtca	tgctgtatgt tggctatgt	360
cgtggcacaa agtgcatttgc gctgtaaacc cagaggcaga	attattgcct gaatgacctg	420
cgcggaaaag aactgcggga tatgaccgtg ggtgttttag	gaactggcg aatcgacag	480
gcagtcatgg agcgccttgg gggattcggt tgtaaggtat	tggcgtatgca cggaaatcaa	540
aaagcaggag cagactatgt ttcgttcat gaactgtca	aaaaaagtga cattgttaca	600
ctgcataatcc ctgtggcgga ggataccccgc	catatgattt gctatgaa gctggaaatg	660
atgaaggaag aggcgttct gatcaataca gggcgcccc	cttagtggat taccgcagca	720
tggtagaaag cattaaaagg acagaaaatc ggccggcccc	tggatgtttt ggaaggcgaa	780
gaaggtatct ttaccatga ctgcacccaa agaagaatag	aacatcctt cctgtcggtc	840
ctgcaggaa tgccgaatgt cattgttacg ccgcacacag	cctatcatac ggaacgggtg	900
tggttgaca cggtcagaaa tactattaga aattgtttga	attttgaaag gagtctggaa	960
aatgttttag		969

<210> 38

<211> 1032

<212> DNA

<213> Enterococcus faecium

<400> 38

atgttttagaa taaaagttgc agttctgttt gggggctgtt	cagaggaaca taatgtttcg	60
ataaaatctg cgatggagat tgccgaaac atagatacaa	aaaaatatca gccttattat	120
atggaaatca caaaatccgg cgtttggaaa atgtgtgaaa	aacctgttt ggagtggaa	180
caatatgcgg gggatccggt tgtttttgc ccggacagaa	gtacgcattt tctgtgtata	240
caaaaagaca aagggtatga aatccagctt gtggatgtgg	tgtttccgat gattcatggc	300
aagtttgggg aggatggctc catacaaggc ttgttgcata	tgcaggcat tccgtatgt	360

-19-

ggatgcgata ttcaaagctc cgtgatctgc atggataagg cgcttgcata taccgttgc	420
aaaaatgcgg gtatcactgt gcctgggttc cggatccttc aggaggggaa tcgcctggaa	480
acggaggatt tcgttatatcc cggtttgtta aagcctgccc gtccggctc atcccttggc	540
gtaaacaagg tatgcaaggc agaagaactg cagggcagcaa tcaagaagaac aagaaaatat	600
gacagcaaga ttttgattga agaggccgtt accgggagtg agttaggctg cgccatactg	660
ggaaacggaa atgatctcat ggctggcgag gtggatcaga ttgagcttag acacggctt	720
ttaaagatcc atcaggaagc acagccggag aaggatctg aaaatgcagt catccgagtt	780
ccagccgcct taccggatga ggttaagagaa cagattcagg aaacggcaat gaagatttac	840
cggatacttg gctgcagagg attggccgc attgacctgt tttgcggga ggacggttgc	900
attgtgtca atgaagtcaa taccatgcca ggtttactt cctacagccg ctatccccgc	960
atgatgacag cagccggttt tacgctttct gaaatactgg atcgcttgat tgaactttca	1020
cttaggaggt aa	1032

<210> 39

<211> 609

<212> DNA

<213> Enterococcus faecium

<400> 39

ataaaaaaga actttgcctt ttttagatcaa atgattcccg ggatccgatg ggatccaaa	60
tatgccacct gggacaattt caccggaaa ccggtagacg gatacatggt aaaccgtgtt	120
atgggaacga aggagctggg agttgtttt cgtaaggctc agaagatggc ggagaagcta	180
ggatatggtt tgctcttatg ggacggctat cgccccagt gcgcagtgaa ttgtttctg	240
aattggcctt cccaaaccgga agacaatctg acgaaaaaagc gtactatcc aaatatcaa	300
aggaatgaga tggttgcgaa ggggtatgtg gcctcacaat ccagccacag ccgtggaaagt	360
acggttgacc ttacaattt tcatttgaat agcggtatgc ttgttcctat gggtggagat	420
tttgacttta tggatgaacg gtacacaccat gccgcaagcg gtctgagcga agaagaatca	480
aaaaaaccggc agtgcttgcg ttatatcatg gagagtatcg gatttgaagc ctatcgat	540
aatgggtggc attacgtctt ggccggacgag ccatacccg atacatattt tgattttgc	600
attgcctag	609

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A3

(51) International Patent Classification⁷: C07K 14/315,
C12N 15/11, 15/52

Longfellow Road, Wellesley Hills, MA 02481-5220 (US).
GOLD, Howard [US/US]; Apartment 610, 135 Pleasant
Street, Brookline, MA 02446-3489 (US). **ELIOPOULOS,**
George, M. [US/US]; 5 Laurel Circle, Needham, MA
02494 (US).

(21) International Application Number: PCT/US00/22086

(74) Agent: **PLUMER, Elizabeth, R.**; Wolf, Greenfield &
Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(22) International Filing Date: 11 August 2000 (11.08.2000)

(81) Designated States (*national*): CA, JP, US.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(26) Publication Language: English

Published:

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

— with international search report


(71) Applicant (*for all designated States except US*): **BETH**
ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).

(88) Date of publication of the international search report:
18 October 2001

(72) Inventors; and


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(75) Inventors/Applicants (*for US only*): **INOUE, Roger, T.** [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). **TORRES-VIERA, Carlos** [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas, Venezuela (VE). **MOELLERING, Robert** [US/US]; 49



WO 01/12803 A3

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT ENTEROCOCCUS



(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *VanR*-responsive promoter decoy.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/22086

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/315 C12N15/11 C12N15/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 07942 A (PASTEUR INSTITUT) 14 May 1992 (1992-05-14)	24-27,29
Y	the whole document, in particular pages 7, 46 and 51	1-6,8, 10-17,19
Y	---	1-17,19
Y	WO 90 00624 A (Baylor COLLEGE MEDICINE) 25 January 1990 (1990-01-25) the whole document, in particular page 4 line 7 to page 5 line 25	---
A	PETER MITCHELL: "Facing up to antibiotic resistance" PHARMAPROJECTS MAGAZINE, vol. 3, no. 8, June 1998 (1998-06), pages 16-20, XP000943900 the whole document, in particular pages 18-19	1-23,28

	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

5 March 2001

Date of mailing of the international search report

18.04.01

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Julia, P

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 00/22086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 12205 A (VIRUS RESEARCH INST INC ;BEATTIE DAVID T (US)) 26 March 1998 (1998-03-26) page 3 last paragraph to page 4 first paragraph ---	1-23,28
X	WO 96 08582 A (BERGERON MICHEL G ;OUELLETTE MARC (CA); ROY PAUL H (CA)) 21 March 1996 (1996-03-21) the whole document, in particular page 17, page 24 example 9, page 26 example 13 and Table 8 ---	24-26
P,X	DATABASE GALE GROUP NEWSLETTER DB [Online] D.J. DENOON: "Gene-Based strategy reverses vancomycin resistance" XP002154962 Database accession number 56646980 abstract & Gene Therapy Weekly 1999, Oct 18 ---	1-6, 10-23,28
Y	STEFAN EVERAERT AND PATRICE COURVALIN: "Regulation of VanB-type vancomycin resistance gene expression by the VanSB-VanRB two-component regulatory system in Enterococcus faecalis V583" JOURNAL OF BACTERIOLOGY, vol. 178, no. 5, March 1996 (1996-03), pages 1302-1309, XP002153486 US the whole document ---	1-5,7, 13-15
X	WO 94 14961 A (PASTEUR INSTITUT ;ARTHUR MICHEL (FR); DUTKA MALEN SYLVIE (FR); EVE) 7 July 1994 (1994-07-07)	24,25,27
Y	the whole document, in particular pages 6 and 8-10 ---	1-5,7, 13-15
Y	F. NAVARRO AND P. COURVALIN: "Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliiflavus and Enterococcus flavescentis" ANTIMICROB AGENTS CHEMOTHER, vol. 38, no. 8, August 1994 (1994-08), pages 1788-1793, XP000984075 the whole document ---	1-5,8, 13-15
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No PCT/JS 00/22086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	B. CASADEWALL AND P. COURVALIN: "Characterization of the VanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339" JOURNAL OF BACTERIOLOGY, vol. 181, no. 12, June 1999 (1999-06), pages 3644-3648, XP002153485 US the whole document ---	1-5,9, 13-15
X	WO 99 01571 A (MODRUSAN ZORA D ;ID BIOMEDICAL CORP (CA)) 14 January 1999 (1999-01-14) thw whole document, in particular claim 4 ---	24-27
X	M. ARTHUR ET AL., : "Regulated interactions between partner and non-partner sensors and response regulators that control glycopeptide resistance gene expression in enterococci" MICROBIOLOGY, vol. 145, no. PT8, August 1999 (1999-08), pages 1849-1858, XP000986365 the whole document, in particular paragraph bridging pages 1856-1857 and figure 2d ---	20,22
Y	GRISSOM-ARNOLD J ET AL: "INDUCTION OF VANA VANCOMYCIN RESISTANCE GENES IN ENTEROCOCCUS FAECALIS: USE OF A PROMOTER FUSION TO EVALUATE GLYCOPEPTIDE AND NONGLYCOPEPTIDE INDUCTION SIGNALS" MICROBIAL DRUG RESISTANCE, LIEBERT, US, vol. 3, no. 1, 1997, pages 53-64, XP000944092 ISSN: 1076-6294 the whole document, in particular page 61 righth column ---	20,22
Y	MOELLERING R C: "ANTIBIOTIC RESISTANCE: LESSONS FOR THE FUTURE" CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 27, no. SUPP. 01, August 1998 (1998-08), pages S135-S140, XP000943873 ISSN: 1058-4838 the whole document, in particular page S138 righth column last paragraph and page 139 righth column ---	20,22
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/22086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ARTHUR M ET AL: "THE VANS-VANR TWO-COMPONENT REGULATORY SYSTEM CONTROLS SYNTHESIS OF DEPSIPEPTIDE PEPTIDOGLYCAN PRECURSORS IN ENTEROCOCCUS FAECIUM BM4147" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 174, no. 8, April 1992 (1992-04), pages 2582-2591, XP000944110 ISSN: 0021-9193 cited in the application the whole document, in particular page 2587 left column and page 2588 left column second full-paragraph -----</p>	20,22

INTERNATIONAL SEARCH REPORT

Int

ational application No.
PCT/US 00/22086

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-23 as far as they comprise *in vivo* (therapeutic) methods, are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5, 13-15, 24-27, 29 (partial) and 6, 10-12, 16-17, 19 (complete)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising introducing into the organism at least one anti-sense vancomycin resistance molecule under conditions to inhibit expression of a vancomycin resistance gene, wherein said vancomycin resistant organism is a vanA resistant organism and the anti-sense molecule is selected from the group consisting of a vanA antisense molecule, a vanR antisense molecule, a vanS antisense molecule, a vanH antisense molecule, a vanX antisense molecule, a vanY antisense molecule and a vanZ antisense molecule. Said method wherein the anti-sense vancomycin resistance molecule hybridizes to the complete vanA gene sequence or to a conserved region (from 10 to 30 nucleotides) thereof (encodes an active site of the ligase) or to the complete vanX gene sequence or to a conserved region thereof. Said method wherein introducing the anti-sense vancomycin resistance molecule comprises contacting the vancomycin resistant organism with at least one vector (enterococcal shuttle vector, bacteriophage, peptide nucleic acid molecule, enterococcal conjugative transposon or a pheromone-responsive plasmid) comprising one or more vanA "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanA resistance/VanA gene cluster of SEQ ID No.: 1 (which includes vanR, SEQ ID No.: 18; vanS, SEQ ID No.: 19; vanH, SEQ ID No.: 20; vanA, SEQ ID No.: 21; vanX, SEQ ID No.: 22; vanY, SEQ ID No.: 23; vanZ, SEQ ID No.: 24 and conserved sequences thereof) SEQ ID No.: 5-10. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

2. Claims: 1-5, 13-15, 24-27, 29 (partial) and 7 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanB resistant organism and the anti-sense molecule is selected from the group consisting of a vanRB antisense molecule, a vanSB antisense molecule, a vanYB antisense molecule, a vanWB antisense molecule, a vanHB antisense molecule and a vanXB antisense molecule.

An isolated nucleic acid that hybridizes under stringent

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

conditions to a nucleic acid molecule selected from the VanB resistance/VanB gene cluster of SEQ ID No.: 2 (which includes vanRB, SEQ ID No.: 26; vanSB, SEQ ID No.: 27; vanYB, SEQ ID No.: 28; vanHB, SEQ ID No.: 29; vanB, SEQ ID No.: 30; vanXB, SEQ ID No.: 31; vanW, SEQ ID No.: 32 and conserved sequences thereof) SEQ ID No.: 11-12. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

3. Claims: 1-5, 13-15, 24-27, 29 (partial) and 8 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanC resistant organism and the anti-sense molecule is selected from the group consisting of a vanC antisense molecule or vanC-2.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanC resistance (SEQ ID No.: 3) mediated by vanC-2 gene (SEQ ID No.: 33). A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

4. Claims: 1-5, 13-15, 24-27, 29 (partial) and 9 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanD resistant organism and the anti-sense molecule is selected from the group consisting of a vanD antisense molecule, a vanRD antisense molecule, a vanSD antisense molecule, a vanYD antisense molecule, a vanHD antisense molecule and a vanXD antisense molecule.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanD resistance/VanD gene cluster of SEQ ID No.: 4 (which includes vanRD, SEQ ID No.: 34; vanSD, SEQ ID No.: 35; vanYD, SEQ ID No.: 36; vanHD, SEQ ID No.: 37; vanD, SEQ ID No.: 38; vanXD, SEQ ID No.: 39 and conserved sequences thereof) SEQ ID No.: 13. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

5. Claim : 20 and 22 (partial)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising enhancing expression of a vanH promoter in the organism, wherein the vanH promoter is not operatively coupled to a vancomycin resistance gene of the organism. Said method wherein the vanH promoter is contained on an enterococcus vector and enhancing expression comprises introducing into the organism

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

an amount of vector to express an amount of the vanH promoter sufficient to bind to phosphorylated VanR and thereby reduce vancomycin resistance in the organism.

6. Claims: 18, 21, 23, 28 (complete) and 20, 22 (partial)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising enhancing expression of a vanH promoter in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the vanH promoter is operatively coupled to an antisense vancomycin resistance molecule (or if not operatively coupled then an antisense vancomycin resistance molecule operatively coupled to a vanH promoter is coadministered). Said method wherein the vanH promoter and the antisense vancomycin resistance molecule are contained on an enterococcus vector and enhancing expression comprises introducing into the organism an amount of vector to express an amount of the vanH promoter sufficient to bind to phosphorylated VanR and thereby reduce vancomycin resistance in the organism.

A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising introducing into the organism a vector comprising a VanR-responsive promoter (vanH) operatively coupled to the vanA antisense molecule. A vector comprising a vanH promoter operatively coupled to an isolated nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID No.: 1-13. An isolated vancomycin resistant organism comprising such a vector.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/22086

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9207942 A	14-05-1992	FR 2668489 A		30-04-1992
		CA 2072350 A		01-05-1992
		EP 0507934 A		14-10-1992
		JP 5503222 T		03-06-1993
		US 5871910 A		16-02-1999
		US 6013508 A		11-01-2000
WO 9000624 A	25-01-1990	AT 137806 T		15-05-1996
		AU 4180889 A		05-02-1990
		DE 68926455 D		13-06-1996
		DE 68926455 T		31-10-1996
		EP 0424473 A		02-05-1991
		JP 3505672 T		12-12-1991
		US 5294533 A		15-03-1994
WO 9812205 A	26-03-1998	AU 4485897 A		14-04-1998
WO 9608582 A	21-03-1996	AU 705198 B		20-05-1999
		AU 3468195 A		29-03-1996
		BR 9508918 A		21-10-1997
		CA 2199144 A		21-03-1996
		EP 0804616 A		05-11-1997
		JP 10504973 T		19-05-1998
		NO 971111 A		09-05-1997
		NZ 292494 A		25-03-1998
		US 6001564 A		14-12-1999
WO 9414961 A	07-07-1994	FR 2699539 A		24-06-1994
		FR 2699537 A		24-06-1994
		CA 2152066 A		07-07-1994
		EP 0672147 A		20-09-1995
		JP 8505050 T		04-06-1996
		US 6087106 A		11-07-2000
		US 5770361 A		23-06-1998
WO 9901571 A	14-01-1999	AU 8327398 A		25-01-1999
		EP 0996743 A		03-05-2000